<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523418310341</prism:url><dc:identifier>doi:10.1016/j.ejmech.2018.11.072</dc:identifier><eid>1-s2.0-S0223523418310341</eid><prism:doi>10.1016/j.ejmech.2018.11.072</prism:doi><pii>S0223-5234(18)31034-1</pii><dc:title>Targeting the immunity protein kinases for immuno-oncology </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>02235234</prism:issn><prism:volume>163</prism:volume><prism:startingPage>413</prism:startingpage><prism:endingPage>427</prism:endingpage><prism:pageRange>413-427</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2019-02-01</prism:coverdate><prism:coverDisplayDate>1 February 2019</prism:coverdisplaydate><prism:copyright>© 2018 Published by Elsevier Masson SAS.</prism:copyright><prism:publisher>Published by Elsevier Masson SAS.</prism:publisher><dc:creator>Yuan, Xinrui</dc:creator><dc:creator>Wu, Hanshu</dc:creator><dc:creator>Bu, Hong</dc:creator><dc:creator>Zhou, Jinpei</dc:creator><dc:creator>Zhang, Huibin</dc:creator><dc:description>
                  With the rise of immuno-oncology, small-molecule modulators targeting immune system and inflammatory processes are becoming a research hotspot. This work mainly focuses on key kinases acting as central nodes in immune signaling pathways. Although over thirty small-molecule kinase inhibitors have been approved by FDA for the treatment of various cancers, only a few are associated with immuno-oncology. With the going deep of the research work, more and more immunity protein kinase inhibitors are approved for clinical trials to treat solid tumors and hematologic malignancies by FDA, which remain good prospects. Meanwhile, in-depth understanding of biological function of immunity protein kinases in immune system is pushing the field forward. This article focuses on the development of safe and effective small-molecule immunity protein kinase inhibitors and further work needs to keep the promises of these inhibitors for patients’ welfare.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Immuno-oncology</dcterms:subject><dcterms:subject>Immunity protein kinases</dcterms:subject><dcterms:subject>Small-molecules inhibitors</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523418310341" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523418310341" rel="scidir"/></link></coredata><objects><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="242" height="245" size="26251">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="82" height="46" size="1665">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="101" height="40" size="1515">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="79" height="60" size="1581">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="70" height="52" size="1622">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="124" height="42" size="2144">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="120" height="47" size="1849">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx15.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="93" height="48" size="1760">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="94" height="52" size="1744">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="70" height="90" size="2331">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="70" height="86" size="2278">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="70" height="106" size="2363">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="70" height="104" size="2259">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="70" height="90" size="2260">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="82" height="46" size="1575">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="388" height="222" size="17433">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="388" height="232" size="25922">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="493" height="158" size="18627">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr11.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="495" height="184" size="33049">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr12.jpg?httpAccept=%2A%2F%2A</object><object ref="gr13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="212" size="15140">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr13.jpg?httpAccept=%2A%2F%2A</object><object ref="gr14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="101" size="9598">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr14.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="382" height="109" size="11976">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="388" height="263" size="31692">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="511" height="175" size="27051">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="511" height="238" size="32375">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="388" height="200" size="25839">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="355" height="183" size="14881">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="357" height="366" size="41574">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="488" height="240" size="23629">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="162" height="164" size="6766">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="124" size="4172">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="87" size="3086">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="217" height="164" size="4257">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="164" size="4980">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="fx14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="74" size="3038">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx14.sml?httpAccept=%2A%2F%2A</object><object ref="fx15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="86" size="3197">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx15.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="4015">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="120" size="3625">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="128" height="164" size="3750">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="134" height="164" size="3825">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="108" height="163" size="3164">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="110" height="163" size="2973">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="128" height="164" size="3628">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="122" size="3968">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="125" size="7164">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="131" size="7262">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="70" size="3873">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr11.sml?httpAccept=%2A%2F%2A</object><object ref="gr12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="81" size="10399">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr12.sml?httpAccept=%2A%2F%2A</object><object ref="gr13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="120" size="4271">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr13.sml?httpAccept=%2A%2F%2A</object><object ref="gr14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="57" size="3037">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr14.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="62" size="3804">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="149" size="10447">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="75" size="4260">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="102" size="4952">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="7799">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="4678">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="160" height="164" size="11927">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="108" size="4581">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1073" height="1085" size="167118">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="367" height="208" size="11939">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="447" height="177" size="10337">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="352" height="266" size="11404">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="312" height="233" size="11111">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="551" height="185" size="14641">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="532" height="210" size="14922">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="414" height="213" size="12769">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="417" height="229" size="12259">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="311" height="398" size="17552">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="311" height="381" size="16796">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="314" height="474" size="18317">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="314" height="466" size="17014">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="311" height="399" size="17315">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="364" height="203" size="11308">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1721" height="985" size="153764">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1721" height="1029" size="189248">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2185" height="700" size="144067">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2193" height="814" size="278595">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1713" height="940" size="129576">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1713" height="447" size="72718">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1691" height="482" size="98496">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1721" height="1168" size="214495">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2264" height="774" size="225742">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2264" height="1056" size="261426">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1721" height="886" size="187848">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1575" height="813" size="122120">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1583" height="1625" size="330538">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2162" height="1062" size="186118">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418310341-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object></objects><scopus-id>85057614028</scopus-id><scopus-eid>2-s2.0-85057614028</scopus-eid><pubmed-id>30530193</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85057614028" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20181204">2018-12-04</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20181204">2018-12-04</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20181207">2018-12-07</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20181207">2018-12-07</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-01-06T12:42:56</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523418310341</xocs:eid>
      <xocs:pii-formatted>S0223-5234(18)31034-1</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523418310341</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2018.11.072</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.4</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523418X00208</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210106">2021-01-06T14:13:42.990561Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20190201</xocs:date-search-begin>
      <xocs:year-nav>2019</xocs:year-nav>
      <xocs:indexeddate epoch="1543909573">2018-12-04T07:46:13.573275Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>163</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>163</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 163</xocs:vol-iss-suppl-text>
      <xocs:sort-order>4</xocs:sort-order>
      <xocs:first-fp>413</xocs:first-fp>
      <xocs:last-lp>427</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>413</xocs:first-page>
         <xocs:last-page>427</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20190201</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>1 February 2019</xocs:cover-date-text>
      <xocs:cover-date-start>2019-02-01</xocs:cover-date-start>
      <xocs:cover-date-year>2019</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Review articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>© 2018 Published by Elsevier Masson SAS.</xocs:copyright-line>
      <xocs:normalized-article-title>TARGETINGIMMUNITYPROTEINKINASESFORIMMUNOONCOLOGY</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>YUAN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>X</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Small molecules targeting the immunity protein kinases</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>MNK inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>PI3Kδ and PI3Kγ</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>TYK2</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>TGFBR1/ALK5</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>PIM</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>IRAK4</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>RON/MST1R</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion and future perspectives</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>BRYAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>9030</xocs:ref-first-fp>
            <xocs:ref-last-lp>9058</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>NATHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>846</xocs:ref-first-fp>
            <xocs:ref-last-lp>852</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>DREAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>3025</xocs:ref-first-fp>
            <xocs:ref-last-lp>3053</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>SCHMID</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>715</xocs:ref-first-fp>
            <xocs:ref-last-lp>727</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>GAESTEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>480</xocs:ref-first-fp>
            <xocs:ref-last-lp>499</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>HAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>3034</xocs:ref-first-fp>
            <xocs:ref-last-lp>3045</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>WEBSTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>PR11</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>WENDEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>3232</xocs:ref-first-fp>
            <xocs:ref-last-lp>32237</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>SONALI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>127</xocs:ref-first-fp>
            <xocs:ref-last-lp>139</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>DE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>59</xocs:ref-first-fp>
            <xocs:ref-last-lp>72</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>KLEINER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>5</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>DASILVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1898</xocs:ref-first-fp>
            <xocs:ref-last-lp>1907</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>BUXADE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>177</xocs:ref-first-fp>
            <xocs:ref-last-lp>189</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>BUXADE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>57</xocs:ref-first-fp>
            <xocs:ref-last-lp>65</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>HEFNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>37542</xocs:ref-first-fp>
            <xocs:ref-last-lp>37551</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>UEDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>6539</xocs:ref-first-fp>
            <xocs:ref-last-lp>6549</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>JOSHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>321</xocs:ref-first-fp>
            <xocs:ref-last-lp>333</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>UEDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>13984</xocs:ref-first-fp>
            <xocs:ref-last-lp>13990</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>KNAUF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>5500</xocs:ref-first-fp>
            <xocs:ref-last-lp>5511</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>WHEATER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>728</xocs:ref-first-fp>
            <xocs:ref-last-lp>735</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>EVANS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1726</xocs:ref-first-fp>
            <xocs:ref-last-lp>1738</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>SCHENONE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>7189</xocs:ref-first-fp>
            <xocs:ref-last-lp>7238</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>ZUCCOTTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>2681</xocs:ref-first-fp>
            <xocs:ref-last-lp>2694</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24"/></xocs:ref-info>
         <xocs:ref-info refid="sref25"/></xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>SANTAG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>21</xocs:ref-first-fp>
            <xocs:ref-last-lp>29</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>SANTAG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>2604</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>WEBSTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1554</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>GOPAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>4624</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>4348</xocs:ref-first-fp>
            <xocs:ref-last-lp>4369</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>TENEGGI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>S89</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>TIMOTHY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>8559</xocs:ref-first-fp>
            <xocs:ref-last-lp>8581</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>WILLIAMS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>123</xocs:ref-first-fp>
            <xocs:ref-last-lp>134</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>VANHAESEBROECK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>329</xocs:ref-first-fp>
            <xocs:ref-last-lp>341</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>OKKENHAUG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1090</xocs:ref-first-fp>
            <xocs:ref-last-lp>1105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>ALI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>407</xocs:ref-first-fp>
            <xocs:ref-last-lp>411</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>ROYCHOUDHURI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>101</xocs:ref-first-fp>
            <xocs:ref-last-lp>111</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>FU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>3436</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>FOUBERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>957</xocs:ref-first-fp>
            <xocs:ref-last-lp>968</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>KANEDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>437</xocs:ref-first-fp>
            <xocs:ref-last-lp>442</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>BROWN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>3390</xocs:ref-first-fp>
            <xocs:ref-last-lp>3397</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>SHIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>120</xocs:ref-first-fp>
            <xocs:ref-last-lp>130</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>EVANS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>862</xocs:ref-first-fp>
            <xocs:ref-last-lp>867</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>HENAU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>S554</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>HENAU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>443</xocs:ref-first-fp>
            <xocs:ref-last-lp>447</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>REIF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>2236</xocs:ref-first-fp>
            <xocs:ref-last-lp>2240</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>FLINN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>877</xocs:ref-first-fp>
            <xocs:ref-last-lp>887</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>HORWITZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>888</xocs:ref-first-fp>
            <xocs:ref-last-lp>898</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>WINKLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1364</xocs:ref-first-fp>
            <xocs:ref-last-lp>1374</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>COUTRE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>2779</xocs:ref-first-fp>
            <xocs:ref-last-lp>2786</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>HIRSCH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>1049</xocs:ref-first-fp>
            <xocs:ref-last-lp>1053</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>SIRAGUSA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>757</xocs:ref-first-fp>
            <xocs:ref-last-lp>768</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>STROBL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3214</xocs:ref-first-fp>
            <xocs:ref-last-lp>3232</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>GHORESCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>273</xocs:ref-first-fp>
            <xocs:ref-last-lp>287</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>VELAZQUEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1992</xocs:ref-pub-year>
            <xocs:ref-first-fp>313</xocs:ref-first-fp>
            <xocs:ref-last-lp>322</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>LEITNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>209</xocs:ref-first-fp>
            <xocs:ref-last-lp>218</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>NEUBAUER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>397</xocs:ref-first-fp>
            <xocs:ref-last-lp>409</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>RODIG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>373</xocs:ref-first-fp>
            <xocs:ref-last-lp>383</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>NOSAKA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>800</xocs:ref-first-fp>
            <xocs:ref-last-lp>802</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>771</xocs:ref-first-fp>
            <xocs:ref-last-lp>782</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>TAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>4663</xocs:ref-first-fp>
            <xocs:ref-last-lp>4672</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>CUNNINGHAME</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>BAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1309</xocs:ref-first-fp>
            <xocs:ref-last-lp>1313</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>DIOGO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>MARROQUI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>3808</xocs:ref-first-fp>
            <xocs:ref-last-lp>3817</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>IDE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>292</xocs:ref-first-fp>
            <xocs:ref-last-lp>296</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>UBEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>STOIBER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1650</xocs:ref-first-fp>
            <xocs:ref-last-lp>1658</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref69">
            <xocs:ref-normalized-surname>MICHAELA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref70">
            <xocs:ref-normalized-surname>AKAHANE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>271</xocs:ref-first-fp>
            <xocs:ref-last-lp>282</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref71">
            <xocs:ref-normalized-surname>MASSE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>POTENTSELECTIVETYK2INHIBITORSBLOCKTH1TH17MEDIATEDIMMUNERESPONSESREDUCEDISEASEPROGRESSIONINRODENTMODELSDELAYEDTYPEHYPERSENSITIVITYPSORIASIS</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref72">
            <xocs:ref-normalized-surname>READER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>S22</xocs:ref-first-fp>
            <xocs:ref-last-lp>S23</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref73">
            <xocs:ref-normalized-surname>JIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>4213</xocs:ref-first-fp>
            <xocs:ref-last-lp>4238</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref74">
            <xocs:ref-normalized-surname>WALKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1994</xocs:ref-pub-year>
            <xocs:ref-first-fp>1160</xocs:ref-first-fp>
            <xocs:ref-last-lp>1165</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref75">
            <xocs:ref-normalized-surname>RIFKIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>7409</xocs:ref-first-fp>
            <xocs:ref-last-lp>7412</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref76">
            <xocs:ref-normalized-surname>SHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>685</xocs:ref-first-fp>
            <xocs:ref-last-lp>700</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref77">
            <xocs:ref-normalized-surname>PICKUP</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>788</xocs:ref-first-fp>
            <xocs:ref-last-lp>799</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref78">
            <xocs:ref-normalized-surname>OHNUKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref79">
            <xocs:ref-normalized-surname>MASSAGUE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>169</xocs:ref-first-fp>
            <xocs:ref-last-lp>178</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref80">
            <xocs:ref-normalized-surname>DERYNCK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>577</xocs:ref-first-fp>
            <xocs:ref-last-lp>584</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref81">
            <xocs:ref-normalized-surname>AKHURST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>790</xocs:ref-first-fp>
            <xocs:ref-last-lp>811</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref82">
            <xocs:ref-normalized-surname>DERYNCK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>117</xocs:ref-first-fp>
            <xocs:ref-last-lp>129</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref83">
            <xocs:ref-normalized-surname>SAFINA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>2407</xocs:ref-first-fp>
            <xocs:ref-last-lp>2422</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref84">
            <xocs:ref-normalized-surname>ESQUELAKERSCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>259</xocs:ref-first-fp>
            <xocs:ref-last-lp>269</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref85">
            <xocs:ref-normalized-surname>SARTOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>456</xocs:ref-first-fp>
            <xocs:ref-last-lp>463</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref86">
            <xocs:ref-normalized-surname>BUENO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>142</xocs:ref-first-fp>
            <xocs:ref-last-lp>150</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref87">
            <xocs:ref-normalized-surname>BHOLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1348</xocs:ref-first-fp>
            <xocs:ref-last-lp>1358</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref88">
            <xocs:ref-normalized-surname>YOON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1720</xocs:ref-first-fp>
            <xocs:ref-last-lp>1739</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref89">
            <xocs:ref-normalized-surname>FUJIWARA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1143</xocs:ref-first-fp>
            <xocs:ref-last-lp>1152</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref90">
            <xocs:ref-normalized-surname>RODON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>357</xocs:ref-first-fp>
            <xocs:ref-last-lp>370</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref91">
            <xocs:ref-normalized-surname>RODON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>553</xocs:ref-first-fp>
            <xocs:ref-last-lp>560</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref92">
            <xocs:ref-normalized-surname>KOVACS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>309</xocs:ref-first-fp>
            <xocs:ref-last-lp>323</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref93"/></xocs:ref-info>
         <xocs:ref-info refid="sref94">
            <xocs:ref-normalized-surname>KAZUHITO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>140</xocs:ref-first-fp>
            <xocs:ref-last-lp>148</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref95">
            <xocs:ref-normalized-surname>CONNOLLY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>964</xocs:ref-first-fp>
            <xocs:ref-last-lp>978</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref96">
            <xocs:ref-normalized-surname>TAKEUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref97">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>72</xocs:ref-first-fp>
            <xocs:ref-last-lp>80</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref98">
            <xocs:ref-normalized-surname>MOHAMMAD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>175</xocs:ref-first-fp>
            <xocs:ref-last-lp>184</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref99">
            <xocs:ref-normalized-surname>WEINMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>450</xocs:ref-first-fp>
            <xocs:ref-last-lp>466</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref100">
            <xocs:ref-normalized-surname>ANDERTON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>916</xocs:ref-first-fp>
            <xocs:ref-last-lp>924</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref101">
            <xocs:ref-normalized-surname>AMARAVADI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>2618</xocs:ref-first-fp>
            <xocs:ref-last-lp>2624</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref102">
            <xocs:ref-normalized-surname>LOSMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>405</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref103">
            <xocs:ref-normalized-surname>SWORDS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2059</xocs:ref-first-fp>
            <xocs:ref-last-lp>2066</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref104">
            <xocs:ref-normalized-surname>AKASAKA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2335</xocs:ref-first-fp>
            <xocs:ref-last-lp>2341</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref105">
            <xocs:ref-normalized-surname>AMSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1989</xocs:ref-pub-year>
            <xocs:ref-first-fp>8857</xocs:ref-first-fp>
            <xocs:ref-last-lp>8861</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref106">
            <xocs:ref-normalized-surname>XIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2655</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>ASHANNUALMEETINGABSTRACTS</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>PKC412DIRECTLYINHIBITSSERINETHREONINEPROTEINKINASEPIM1INCELLLINESACUTEMYELOIDLEUKEMIACELLSANOVELMECHANISMINHIBITIONMULTIDRUGRESISTANCE</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sref107">
            <xocs:ref-normalized-surname>JINESH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1203</xocs:ref-first-fp>
            <xocs:ref-last-lp>1213</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref108">
            <xocs:ref-normalized-surname>DENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>20211</xocs:ref-first-fp>
            <xocs:ref-last-lp>20220</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref109">
            <xocs:ref-normalized-surname>DAENTHANASANMAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>815</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref110">
            <xocs:ref-normalized-surname>PLYM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>448</xocs:ref-first-fp>
            <xocs:ref-last-lp>460</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref111">
            <xocs:ref-normalized-surname>JACKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>200</xocs:ref-first-fp>
            <xocs:ref-last-lp>213</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref112">
            <xocs:ref-normalized-surname>BIALOPIOTROWICZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>e3239</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref113">
            <xocs:ref-normalized-surname>BLANCOAPARICIO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>629</xocs:ref-first-fp>
            <xocs:ref-last-lp>643</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref114">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>3491</xocs:ref-first-fp>
            <xocs:ref-last-lp>3500</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref115">
            <xocs:ref-normalized-surname>PAINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>225</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref116">
            <xocs:ref-normalized-surname>RAAB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>3186</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref117">
            <xocs:ref-normalized-surname>KEANE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>e325</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref118">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>5521</xocs:ref-first-fp>
            <xocs:ref-last-lp>5542</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref119">
            <xocs:ref-normalized-surname>SUZUKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>503</xocs:ref-first-fp>
            <xocs:ref-last-lp>506</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref120">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>614</xocs:ref-first-fp>
            <xocs:ref-last-lp>618</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref121">
            <xocs:ref-normalized-surname>KOZICZAKHOLBRO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1661</xocs:ref-first-fp>
            <xocs:ref-last-lp>1671</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref122">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>5567</xocs:ref-first-fp>
            <xocs:ref-last-lp>5572</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref123">
            <xocs:ref-normalized-surname>SUZUKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>566</xocs:ref-first-fp>
            <xocs:ref-last-lp>572</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref124">
            <xocs:ref-normalized-surname>KAWAGOE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1013</xocs:ref-first-fp>
            <xocs:ref-last-lp>1024</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref125">
            <xocs:ref-normalized-surname>VON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>691</xocs:ref-first-fp>
            <xocs:ref-last-lp>696</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref126">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>465</xocs:ref-first-fp>
            <xocs:ref-last-lp>478</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref127">
            <xocs:ref-normalized-surname>KU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>2407</xocs:ref-first-fp>
            <xocs:ref-last-lp>2422</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref128">
            <xocs:ref-normalized-surname>KOZICZAKHOLBRO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>63</xocs:ref-first-fp>
            <xocs:ref-last-lp>82</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>ERNSTSCHERINGFOUNDSYMPPROC2007</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>SOLVINGIRAK4ENIGMAAPPLICATIONKINASEDEADKNOCKINMICE</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sref129">
            <xocs:ref-normalized-surname>SUZUKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>750</xocs:ref-first-fp>
            <xocs:ref-last-lp>756</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref130">
            <xocs:ref-normalized-surname>SRIVASTAVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6209</xocs:ref-first-fp>
            <xocs:ref-last-lp>6216</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref131">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1081</xocs:ref-first-fp>
            <xocs:ref-last-lp>1097</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref132">
            <xocs:ref-normalized-surname>KELLY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>2189</xocs:ref-first-fp>
            <xocs:ref-last-lp>2201</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref133">
            <xocs:ref-normalized-surname>WOOD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>3833</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref134">
            <xocs:ref-normalized-surname>SCOTT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>10071</xocs:ref-first-fp>
            <xocs:ref-last-lp>10091</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref135">
            <xocs:ref-normalized-surname>KRETSCHMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1157</xocs:ref-first-fp>
            <xocs:ref-last-lp>1168</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref136">
            <xocs:ref-normalized-surname>WALTZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>567</xocs:ref-first-fp>
            <xocs:ref-last-lp>576</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref137">
            <xocs:ref-normalized-surname>MORRISON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1825</xocs:ref-first-fp>
            <xocs:ref-last-lp>1832</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref138">
            <xocs:ref-normalized-surname>WELM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>7570</xocs:ref-first-fp>
            <xocs:ref-last-lp>7575</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref139">
            <xocs:ref-normalized-surname>EYOB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref140">
            <xocs:ref-normalized-surname>SHARDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2181</xocs:ref-first-fp>
            <xocs:ref-last-lp>2192</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref141">
            <xocs:ref-normalized-surname>EYOB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>751</xocs:ref-first-fp>
            <xocs:ref-last-lp>760</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>YUANX2019X413</xocs:refkey3>
         <xocs:refkey4lp>YUANX2019X413X427</xocs:refkey4lp>
         <xocs:refkey4ai>YUANX2019X413XX</xocs:refkey4ai>
         <xocs:refkey5>YUANX2019X413X427XX</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2020-12-07T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2020-12-07T00:00:00.000Z</xocs:sa-start-date>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2018 Published by Elsevier Masson SAS.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-03-08T14:44:56.625Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type>
         <xocs:funding-source-document source-document-type="pii">S0223523418310341</xocs:funding-source-document>
         <xocs:funding>
            <xocs:funding-agency-matched-string>Natural Science Foundation of Jiangsu Province</xocs:funding-agency-matched-string>
            <xocs:funding-agency>Natural Science Foundation of Jiangsu Province</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100004608</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding-text>This research was supported by the Natural Science Foundation of Jiangsu Province (No. BK20141349 ) and the China National Key Hi-Tech Innovation Project for the R&D of Novel Drugs (No. 2013ZX09301303-002 ).  </xocs:funding-text>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(18)31034-1</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523418310341</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523418310341</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2018.11.072</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-01-06T14:13:42.990561Z</xocs:timestamp>
         <xocs:cover-date-start>2019-02-01</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/MAIN/application/pdf/3c6d7efc04ecdda21181e3990dba5b11/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2563085</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>15</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523418310341-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/PREVIEW/image/png/6e3a03e8bbbe891a57602d0f59ef2653/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>44515</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx1/DOWNSAMPLED/image/jpeg/6baf7d1bd5bfbbe19a8de366acad3611/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>26251</xocs:filesize>
               <xocs:pixel-height>245</xocs:pixel-height>
               <xocs:pixel-width>242</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx10/DOWNSAMPLED/image/jpeg/cced0f7a6497e1833c3b63b46f375902/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1665</xocs:filesize>
               <xocs:pixel-height>46</xocs:pixel-height>
               <xocs:pixel-width>82</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx11/DOWNSAMPLED/image/jpeg/7249afade8f2e4beec9b781cd5b0ad0f/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1515</xocs:filesize>
               <xocs:pixel-height>40</xocs:pixel-height>
               <xocs:pixel-width>101</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx12/DOWNSAMPLED/image/jpeg/77360a7bb8b7343f4d4f41f1dec5679b/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1581</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>79</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx13/DOWNSAMPLED/image/jpeg/d879ebd830635fecd5cd609d943e8299/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1622</xocs:filesize>
               <xocs:pixel-height>52</xocs:pixel-height>
               <xocs:pixel-width>70</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx14/DOWNSAMPLED/image/jpeg/9e1a59a76847403b3746bd4c348c2615/fx14.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2144</xocs:filesize>
               <xocs:pixel-height>42</xocs:pixel-height>
               <xocs:pixel-width>124</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx15/DOWNSAMPLED/image/jpeg/bc4019297cfc3d072f7703af4ab776fe/fx15.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1849</xocs:filesize>
               <xocs:pixel-height>47</xocs:pixel-height>
               <xocs:pixel-width>120</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx2/DOWNSAMPLED/image/jpeg/0e4ca118b1e3c7cf78bd370570529478/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1760</xocs:filesize>
               <xocs:pixel-height>48</xocs:pixel-height>
               <xocs:pixel-width>93</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx3/DOWNSAMPLED/image/jpeg/3931083adb3d30e862f336ef227bc857/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1744</xocs:filesize>
               <xocs:pixel-height>52</xocs:pixel-height>
               <xocs:pixel-width>94</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx4/DOWNSAMPLED/image/jpeg/b5a0384d437aa7b88af8e85935402186/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2331</xocs:filesize>
               <xocs:pixel-height>90</xocs:pixel-height>
               <xocs:pixel-width>70</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx5/DOWNSAMPLED/image/jpeg/0296881cfa1f6cf320a80d358d7b9ba9/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2278</xocs:filesize>
               <xocs:pixel-height>86</xocs:pixel-height>
               <xocs:pixel-width>70</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx6/DOWNSAMPLED/image/jpeg/38286b31604292c6d304bce337ed3424/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2363</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>70</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx7/DOWNSAMPLED/image/jpeg/65d71a2e6f9c2af3dc7eef019f28a433/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2259</xocs:filesize>
               <xocs:pixel-height>104</xocs:pixel-height>
               <xocs:pixel-width>70</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx8/DOWNSAMPLED/image/jpeg/e48a99f0e92e739af39fccae7a05687c/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2260</xocs:filesize>
               <xocs:pixel-height>90</xocs:pixel-height>
               <xocs:pixel-width>70</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx9/DOWNSAMPLED/image/jpeg/0b46b5a4c7585c83de169a6e156872de/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1575</xocs:filesize>
               <xocs:pixel-height>46</xocs:pixel-height>
               <xocs:pixel-width>82</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr1/DOWNSAMPLED/image/jpeg/f57582ff098f4d858638401abe251136/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>17433</xocs:filesize>
               <xocs:pixel-height>222</xocs:pixel-height>
               <xocs:pixel-width>388</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr10/DOWNSAMPLED/image/jpeg/7806218f87c14693aa5e93db9868ff28/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25922</xocs:filesize>
               <xocs:pixel-height>232</xocs:pixel-height>
               <xocs:pixel-width>388</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr11/DOWNSAMPLED/image/jpeg/fa2e15ff49c75b488fae889d659f1bc1/gr11.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18627</xocs:filesize>
               <xocs:pixel-height>158</xocs:pixel-height>
               <xocs:pixel-width>493</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr12/DOWNSAMPLED/image/jpeg/1f854777ef82c124cebe58d84f30fdf9/gr12.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33049</xocs:filesize>
               <xocs:pixel-height>184</xocs:pixel-height>
               <xocs:pixel-width>495</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr13/DOWNSAMPLED/image/jpeg/fda536a3c82656a713e7cbce58f59b69/gr13.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>15140</xocs:filesize>
               <xocs:pixel-height>212</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr14/DOWNSAMPLED/image/jpeg/ffaf77e2cd86c53246e4c061322ae03b/gr14.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>9598</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr2/DOWNSAMPLED/image/jpeg/89d1c84e8a69df89ece86a554ae49ffd/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>11976</xocs:filesize>
               <xocs:pixel-height>109</xocs:pixel-height>
               <xocs:pixel-width>382</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr3/DOWNSAMPLED/image/jpeg/5f099b176f796d742b10f8a10faa411f/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31692</xocs:filesize>
               <xocs:pixel-height>263</xocs:pixel-height>
               <xocs:pixel-width>388</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr4/DOWNSAMPLED/image/jpeg/80bfe9bf02f746b8eb29909de85122e9/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27051</xocs:filesize>
               <xocs:pixel-height>175</xocs:pixel-height>
               <xocs:pixel-width>511</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr5/DOWNSAMPLED/image/jpeg/7ef777da9f04fed147e4e1f3021f30b6/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>32375</xocs:filesize>
               <xocs:pixel-height>238</xocs:pixel-height>
               <xocs:pixel-width>511</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr6/DOWNSAMPLED/image/jpeg/214f0927a574b3fc7c5cf4341fa11a1a/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25839</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>388</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr7/DOWNSAMPLED/image/jpeg/a63ac4055228bfb16a8b0c5c3b476792/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>14881</xocs:filesize>
               <xocs:pixel-height>183</xocs:pixel-height>
               <xocs:pixel-width>355</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr8/DOWNSAMPLED/image/jpeg/93d5fb8fe6f7f4e59ea4ad8710d62e74/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>41574</xocs:filesize>
               <xocs:pixel-height>366</xocs:pixel-height>
               <xocs:pixel-width>357</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr9/DOWNSAMPLED/image/jpeg/88fa24e995b00139d7e0ec94e1e85e7b/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23629</xocs:filesize>
               <xocs:pixel-height>240</xocs:pixel-height>
               <xocs:pixel-width>488</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx1/THUMBNAIL/image/gif/f781990920f276ef412bcefc23c95185/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6766</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx10/THUMBNAIL/image/gif/e3704bd6e80c4489a994590582b48630/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4172</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx11/THUMBNAIL/image/gif/bd083c0b36fef7ba81eae4998cc15e94/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3086</xocs:filesize>
               <xocs:pixel-height>87</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx12/THUMBNAIL/image/gif/5f6fdd676ab9c0212067adafba98feb2/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4257</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>217</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx13/THUMBNAIL/image/gif/e19d3536e62c4956a20827aeb74229b4/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4980</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx14/THUMBNAIL/image/gif/34dfbf85308847238be03d0aa3135c01/fx14.sml</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3038</xocs:filesize>
               <xocs:pixel-height>74</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx15/THUMBNAIL/image/gif/14f01421a9a06e4f50841090f9e6b443/fx15.sml</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3197</xocs:filesize>
               <xocs:pixel-height>86</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx2/THUMBNAIL/image/gif/f26d4494febbf2b2eae3be4797b3ae16/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4015</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx3/THUMBNAIL/image/gif/3ba87a2ac5f2fc93d11ae5aaf109e685/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3625</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx4/THUMBNAIL/image/gif/eb874556369c34b7e50590bbac6860bc/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3750</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>128</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx5/THUMBNAIL/image/gif/b12cb171041a5fb4940f46b20ce99352/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3825</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>134</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx6/THUMBNAIL/image/gif/237e21401cceffaa3c97eabf7dba2409/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3164</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>108</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx7/THUMBNAIL/image/gif/74ba30cd57eec02408ceceb61f10de1f/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2973</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>110</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx8/THUMBNAIL/image/gif/25cbd1fe8be8bcdcfa2efaaef1b1efa7/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3628</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>128</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx9/THUMBNAIL/image/gif/0282c044e35a1098f265cf799617d422/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3968</xocs:filesize>
               <xocs:pixel-height>122</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr1/THUMBNAIL/image/gif/9e35132b77376a5c7314515774b7818c/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7164</xocs:filesize>
               <xocs:pixel-height>125</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr10/THUMBNAIL/image/gif/7c9e67624b8bc662f0750df447b9e43a/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7262</xocs:filesize>
               <xocs:pixel-height>131</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr11/THUMBNAIL/image/gif/46bb6ccdd51c4d81c209a599cd834a3b/gr11.sml</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3873</xocs:filesize>
               <xocs:pixel-height>70</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr12/THUMBNAIL/image/gif/bdf0a23437fe50802bd3f884e7c7f6b4/gr12.sml</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10399</xocs:filesize>
               <xocs:pixel-height>81</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr13/THUMBNAIL/image/gif/c334c6870308c35bc6bf3a7c85116c70/gr13.sml</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4271</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr14/THUMBNAIL/image/gif/6ac4f62b6661d7b22865a6126162c263/gr14.sml</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3037</xocs:filesize>
               <xocs:pixel-height>57</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr2/THUMBNAIL/image/gif/48082498a2a315730028979c108cda88/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3804</xocs:filesize>
               <xocs:pixel-height>62</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr3/THUMBNAIL/image/gif/1e76c165c93a4b32720c2940fb7defe5/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10447</xocs:filesize>
               <xocs:pixel-height>149</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr4/THUMBNAIL/image/gif/0efa9128517ffda61cf84ab9e297dd64/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4260</xocs:filesize>
               <xocs:pixel-height>75</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr5/THUMBNAIL/image/gif/18a58b1df166ddf047c5822c1d856539/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4952</xocs:filesize>
               <xocs:pixel-height>102</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr6/THUMBNAIL/image/gif/abb7e180ec748f49bd8e1f311df59ffb/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7799</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr7/THUMBNAIL/image/gif/b06bfc9f1436aa34d988131b721edc11/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4678</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr8/THUMBNAIL/image/gif/5aebadccb231b6b62d91e961f9751ac2/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11927</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>160</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr9/THUMBNAIL/image/gif/76ce401fcfd459a8a5197330f4db7d22/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4581</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx1/HIGHRES/image/jpeg/831646203d0782beb2e4d092b1b974de/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>167118</xocs:filesize>
               <xocs:pixel-height>1085</xocs:pixel-height>
               <xocs:pixel-width>1073</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx10/HIGHRES/image/jpeg/462fb3a1ce8a776ae70faf234219fe74/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>11939</xocs:filesize>
               <xocs:pixel-height>208</xocs:pixel-height>
               <xocs:pixel-width>367</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx11/HIGHRES/image/jpeg/b4601375400ed85504ba70c19913d447/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>10337</xocs:filesize>
               <xocs:pixel-height>177</xocs:pixel-height>
               <xocs:pixel-width>447</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx12/HIGHRES/image/jpeg/6d25608d6401364ea5ff8340559d1941/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>11404</xocs:filesize>
               <xocs:pixel-height>266</xocs:pixel-height>
               <xocs:pixel-width>352</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx13/HIGHRES/image/jpeg/111bffb41867bcfca9c3b0657160b5de/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>11111</xocs:filesize>
               <xocs:pixel-height>233</xocs:pixel-height>
               <xocs:pixel-width>312</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx14/HIGHRES/image/jpeg/e2ace9f6d1b2967bc47754d1aa18dae8/fx14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>14641</xocs:filesize>
               <xocs:pixel-height>185</xocs:pixel-height>
               <xocs:pixel-width>551</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx15/HIGHRES/image/jpeg/599a6a6d94a6e1d3c5575a5804c5405e/fx15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>14922</xocs:filesize>
               <xocs:pixel-height>210</xocs:pixel-height>
               <xocs:pixel-width>532</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx2/HIGHRES/image/jpeg/60f125eeeecb1b2cb2d63591437c62b0/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>12769</xocs:filesize>
               <xocs:pixel-height>213</xocs:pixel-height>
               <xocs:pixel-width>414</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx3/HIGHRES/image/jpeg/877d72160d256785795631fccbb0b96c/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>12259</xocs:filesize>
               <xocs:pixel-height>229</xocs:pixel-height>
               <xocs:pixel-width>417</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx4/HIGHRES/image/jpeg/ec9fca8dd89b6b2377546a9a0dd5f61f/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>17552</xocs:filesize>
               <xocs:pixel-height>398</xocs:pixel-height>
               <xocs:pixel-width>311</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx5/HIGHRES/image/jpeg/643771fa39a466e5e78c474d0854ac2b/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>16796</xocs:filesize>
               <xocs:pixel-height>381</xocs:pixel-height>
               <xocs:pixel-width>311</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx6/HIGHRES/image/jpeg/e79abeb461286cab844876a086c004ec/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18317</xocs:filesize>
               <xocs:pixel-height>474</xocs:pixel-height>
               <xocs:pixel-width>314</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx7/HIGHRES/image/jpeg/282c13357a87dfd835791e4d4ef65bd5/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>17014</xocs:filesize>
               <xocs:pixel-height>466</xocs:pixel-height>
               <xocs:pixel-width>314</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx8/HIGHRES/image/jpeg/7cfc3c9bff07fe75102b31643d14e9f5/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>17315</xocs:filesize>
               <xocs:pixel-height>399</xocs:pixel-height>
               <xocs:pixel-width>311</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/fx9/HIGHRES/image/jpeg/b0963c5d4ae6413ad4db0514c73144bf/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>11308</xocs:filesize>
               <xocs:pixel-height>203</xocs:pixel-height>
               <xocs:pixel-width>364</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr1/HIGHRES/image/jpeg/44e022d50115faf773f708eed08e3787/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>153764</xocs:filesize>
               <xocs:pixel-height>985</xocs:pixel-height>
               <xocs:pixel-width>1721</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr10/HIGHRES/image/jpeg/c701fddd0a9dc50a32d3c1a17675e9f2/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>189248</xocs:filesize>
               <xocs:pixel-height>1029</xocs:pixel-height>
               <xocs:pixel-width>1721</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr11/HIGHRES/image/jpeg/2e8d8012d12a70241e777ff191fa17d6/gr11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>144067</xocs:filesize>
               <xocs:pixel-height>700</xocs:pixel-height>
               <xocs:pixel-width>2185</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr12/HIGHRES/image/jpeg/01c75ffd6c7612db341c385ddb10169c/gr12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>278595</xocs:filesize>
               <xocs:pixel-height>814</xocs:pixel-height>
               <xocs:pixel-width>2193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr13/HIGHRES/image/jpeg/c0c219468d7f3be37e5457d716f19e2f/gr13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>129576</xocs:filesize>
               <xocs:pixel-height>940</xocs:pixel-height>
               <xocs:pixel-width>1713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr14/HIGHRES/image/jpeg/ad921a472688702d2ecbe594812c948b/gr14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>72718</xocs:filesize>
               <xocs:pixel-height>447</xocs:pixel-height>
               <xocs:pixel-width>1713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr2/HIGHRES/image/jpeg/5d11bfbc76373bfe8a95c8d9007c8260/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>98496</xocs:filesize>
               <xocs:pixel-height>482</xocs:pixel-height>
               <xocs:pixel-width>1691</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr3/HIGHRES/image/jpeg/d99b79746b0a08116b74cfe53e649818/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>214495</xocs:filesize>
               <xocs:pixel-height>1168</xocs:pixel-height>
               <xocs:pixel-width>1721</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr4/HIGHRES/image/jpeg/a44c95dae634df8fd1e0325b24deefdd/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>225742</xocs:filesize>
               <xocs:pixel-height>774</xocs:pixel-height>
               <xocs:pixel-width>2264</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr5/HIGHRES/image/jpeg/db023a1ff4fcd471fb9a4a088a679cda/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>261426</xocs:filesize>
               <xocs:pixel-height>1056</xocs:pixel-height>
               <xocs:pixel-width>2264</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr6/HIGHRES/image/jpeg/918dd9e57bd1cb0b5ca6229821bab814/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>187848</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>1721</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr7/HIGHRES/image/jpeg/d09e412b5f372949a69e564fce1c4f52/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>122120</xocs:filesize>
               <xocs:pixel-height>813</xocs:pixel-height>
               <xocs:pixel-width>1575</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr8/HIGHRES/image/jpeg/fefef97c711e7690a9482dd03ed2f899/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>330538</xocs:filesize>
               <xocs:pixel-height>1625</xocs:pixel-height>
               <xocs:pixel-width>1583</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418310341-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523418310341/gr9/HIGHRES/image/jpeg/d15608b28e4ed6d8e7ede2fae2784949/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>186118</xocs:filesize>
               <xocs:pixel-height>1062</xocs:pixel-height>
               <xocs:pixel-width>2162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="rev" version="5.5" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>10930</aid>
            <ce:pii>S0223-5234(18)31034-1</ce:pii>
            <ce:doi>10.1016/j.ejmech.2018.11.072</ce:doi>
            <ce:copyright type="unknown" year="2018"/></ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Schematic illustration of MNK-eIF4E signaling pathway. MNK1/2 activated by ERK and p38 MAPK can phosphorylate eIF4E at Ser209 exclusively. Activated eIF4E can recognize and bind with 5′-cap structure (5′-UTR) of mRNA which contains a 7-methylguanosine moiety (m7G). Through interacting with eIF4E and scaffold protein eIF4G, eIF4A, an RNA helicase, can bind with mRNA and unravel secondary structures in 5′-UTR to regulate the translation of mRNA. MNK-eIF4E signaling pathway modulates the production of checkpoint receptors, cytokines and tumor-associated proteins and plays a vital role in the development of cancers.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0015">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Structure of small-molecule inhibitors of MNKs.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0020">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Schematic illustration of PI3Kδ/PI3Kγ signaling pathway. PI3Kδ and PI3Kγ are activated by receptor tyrosine kinase (RTK) and G-protein coupled receptor (GPCR) respectively. Activated PI3Kδ is recruited to plasma membrane by interacting with phosphorylated YXXM motifs on RTKs, and activated PI3Kγ is connected with GPCR-associated G<ce:inf loc="post">βγ</ce:inf> subunit and recruited to plasma membrane. Then PI3Kδ and PI3Kγ can phosphorylate PIP2 to generate PIP3, which regulates various cellular processes by multiple protein kinases-dependent downstream signaling pathways.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0025">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Structure of small-molecule inhibitors of PI3Kδ.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0030">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Structure of PI3Kγ inhibitors and PI3Kγ/δ dual inhibitor.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0035">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Schematic illustration of JAK-STAT signaling pathway. JAKs are activated upon ligand binding to the extracellular domain of receptor complex. JAKs phosphorylate receptor chains, which become docking sites for STATs. Recruited STAT homo- and/or heterodimers are phosphorylated and subsequently translocate to the nucleus, which can induce transcription of target gene.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0040">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Structure of small-molecule inhibitors of TYK2.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0045">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr7"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Schematic diagram of TGF-β signaling pathway. TGF-β feeds through TGFBR2 to activate downstream TGFBR1, which induce the formation, nuclear localization and transcriptional activity of SMAD complex.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0050">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr8"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Structure of small-molecule inhibitors of TGFBR1.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0055">Fig. 9</ce:alt-text>
               <ce:link locator="gr9" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr9"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig. 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Schematic diagram of PIM kinases signaling pathway. Growth factors, death receptor ligands and cytokines can activate PIM kinase signaling pathway and regulate cellular metabolism, cell cycle progression and signal transduction.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0060">Fig. 10</ce:alt-text>
               <ce:link locator="gr10" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr10"/></ce:link>
            </ce:figure>
            <ce:figure id="fig11">
               <ce:label>Fig. 11</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Structure of small-molecule inhibitors of PIM kinases.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0065">Fig. 11</ce:alt-text>
               <ce:link locator="gr11" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr11"/></ce:link>
            </ce:figure>
            <ce:figure id="fig12">
               <ce:label>Fig. 12</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">Schematic diagram of IRAK4 kinases signaling pathway. MyD88 is recruited to IL-1R and TLR4 and mediates the down-stream signaling by IRAK4 and TRAF6. IRAK1 is an essential substrate for the phosphorylation function of IRAK4. IRAK1/2/4 are associated with TRAF6 and subsequent signaling of TAB2/3-JNK and TAK1-IKK, which then lead to the activation of AP-1 and NF-κB respectively.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0070">Fig. 12</ce:alt-text>
               <ce:link locator="gr12" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr12"/></ce:link>
            </ce:figure>
            <ce:figure id="fig13">
               <ce:label>Fig. 13</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="fspara0070" view="all">Structure of small-molecule inhibitors of IRAK4.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0075">Fig. 13</ce:alt-text>
               <ce:link locator="gr13" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr13"/></ce:link>
            </ce:figure>
            <ce:figure id="fig14">
               <ce:label>Fig. 14</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="fspara0075" view="all">Structure of small-molecule inhibitors of RON.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0080">Fig. 14</ce:alt-text>
               <ce:link locator="gr14" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/gr14"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="tspara0010" view="all">Clinical trials developed to assess the safety and potency of small molecules targeting MNK1/2 for oncological applications.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0085">Table 1</ce:alt-text>
               <tgroup cols="6">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Indication (s)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Status</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Notes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Ref.</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>BAY 1143269</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Terminated</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Docetaxel</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02439346</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="3" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx2"/></link>
                              <alt-text role="short" id="alttext0090">Image 2</alt-text>
                           </inline-figure>
                           <br/></br>
                           <bold>eft-508</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02605083</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Triple negative breast cancer; Hepatocellular carcinoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03318562</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Microsatellite stable relapsed or refractory colorectal cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Active, not recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Avelumab</bold> or As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03258398</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lymphoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02937675</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx3"/></link>
                              <alt-text role="short" id="alttext0095">Image 3</alt-text>
                           </inline-figure>
                           <br/></br>
                           <bold>etc-206</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced hematologic malignancies</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Not yet recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Dasatinib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03414450</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl2" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0085">
                  <ce:simple-para id="tspara0015" view="all">Clinical trials developed to assess the safety and potency of small molecules targeting PI3Kδ/γ kinases for oncological applications.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0100">Table 2</ce:alt-text>
               <tgroup cols="6">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Indication (s)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Status</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Notes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Ref.</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx4"/></link>
                              <alt-text role="short" id="alttext0105">Image 4</alt-text>
                           </inline-figure>
                           <br/></br>
                           <bold>idelalisib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Relapsed chronic lymphocytic leukemia; Relapsed small lymphocytic lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Launched</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="4" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx5"/></link>
                              <alt-text role="short" id="alttext0110">Image 5</alt-text>
                           </inline-figure>
                           <br/></br>
                           <bold>umbralisib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Marginal zone lymphoma; Waldenstrom macroglobulinemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03364231</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic Lymphocytic Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Not yet recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Venetoclax</bold> and <bold>Ublituximab</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03379051</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic Lymphocytic Leukemia; B-cell non Hodgkin lymphoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Pembrolizumab</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03283137</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic lymphocytic leukemia; Small lymphocytic lymphoma; Mantle cell lymphoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Ibrutinib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02268851</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Follicular lymphoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with chemotherapy</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03269669</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx6" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx6"/></link>
                              <alt-text role="short" id="alttext0115">Image 6</alt-text>
                           </inline-figure>
                           <br/></br>
                           <bold>dezapelisib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B-cell malignancies</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Active, not recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Itacitinib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01905813</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Refractory Hodgkin lymphoma; Recurrent adult Hodgkin lymphoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Terminated<cross-ref refid="tbl2fna" id="crosref0775">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Itacitinib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02456675</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx7" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx7"/></link>
                              <alt-text role="short" id="alttext0120">Image 7</alt-text>
                           </inline-figure>
                           <br/></br>
                           <bold>ipi-549</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Nivolumab</bold> or as standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02637531</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx8" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx8"/></link>
                              <alt-text role="short" id="alttext0125">Image 8</alt-text>
                           </inline-figure>
                           <br/></br>
                           <bold>duvelisib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">relapsed or refractory chronic lymphocytic leukemia; small lymphocytic lymphoma; relapsed or refractory follicular lymphoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Launched</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0010" view="all">A decision was made due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl3" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0090">
                  <ce:simple-para id="tspara0020" view="all">Clinical trials developed to assess the safety and potency of small molecules targeting TGFBR1 (ALK5) for oncological applications.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0130">Table 3</ce:alt-text>
               <tgroup cols="6">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Indication (s)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Status</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Notes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Ref.</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="4" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx9" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx9"/></link>
                              <alt-text role="short" id="alttext0135">Image 9</alt-text>
                           </inline-figure>
                           <br/></br>
                           <bold>galunisertib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Metastatic pancreatic cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Durvalumab</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02734160</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Neoplasm</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Completed</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02304419</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recurrent or refractory non-small cell lung cancer and hepatocellular carcinoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Nivolumab</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02423343</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced hepatocellular carcinoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with stereotactic body radiotherapy</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02906397</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Metastatic androgen receptor negative triple negative breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In combination with <bold>Paclitaxel</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02672475</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx10" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx10"/></link>
                              <alt-text role="short" id="alttext0140">Image 1</alt-text>
                           </inline-figure>0<br/></br>
                           <bold>Vactosertib</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Myelodysplastic syndromes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03074006</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02160106</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl4" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cap0095">
                  <ce:simple-para id="tspara0025" view="all">Clinical trials developed to assess the safety and potency of small molecules targeting PIM kinases for oncological applications.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0145">Table 4</ce:alt-text>
               <tgroup cols="6">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Indication (s)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Status</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Notes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Ref.</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx11" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx11"/></link>
                              <alt-text role="short" id="alttext0150">Image 1</alt-text>
                           </inline-figure>
                           <br/></br>SGI-1776<cross-ref refid="tbl4fna" id="crosref0780">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Relapsed/refractory leukemias</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Withdrawn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01239108</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Refractory prostate cancer; relapsed/refractory non-Hodgkin's Lymphoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Terminated</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT00848601</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx12" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx12"/></link>
                              <alt-text role="short" id="alttext0155">Image 1</alt-text>
                           </inline-figure>
                           <br/></br>AZD1208</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute myeloid leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Terminated</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01489722</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced solid tumors; malignant lymphoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Completed</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01588548</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx13" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx13"/></link>
                              <alt-text role="short" id="alttext0160">Image 1</alt-text>
                           </inline-figure>
                           <br/></br>PIM-447</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Myelofibrosis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Active, not recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">In Combination With Ruxolitinib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02370706</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl4fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">The dose limiting toxicity of cardiac QTc prolongation was identified and indicated that it was unsafe to continue clinical progress of <ce:bold>SGI-1776</ce:bold>.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl5" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 5</ce:label>
               <ce:caption id="cap0100">
                  <ce:simple-para id="tspara0030" view="all">Clinical trials developed to assess the safety and potency of small molecules targeting RON for oncological applications.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0165">Table 5</ce:alt-text>
               <tgroup cols="6">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Indication (s)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Status</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Notes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Ref.</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx14" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx14"/></link>
                              <alt-text role="short" id="alttext0170">Image 1</alt-text>
                           </inline-figure>
                           <br/></br>
                           <bold>BMS-777607</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced or metastatic solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Completed</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT00605618</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Malignant solid tumor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Completed</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01721148</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx15" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx15"/></link>
                              <alt-text role="short" id="alttext0175">Image 1</alt-text>
                           </inline-figure>
                           <br/></br>
                           <bold>MK-8033</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Advanced solid tumors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Completed</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">As standalone agent</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT00559182</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Review article</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Targeting the immunity protein kinases for immuno-oncology</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523418310341-6609788d13e502c05346e45974253607">
                  <ce:given-name>Xinrui</ce:given-name>
                  <ce:surname>Yuan</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0010">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523418310341-f0607536ba285a1ddfb4b2e5289b4deb">
                  <ce:given-name>Hanshu</ce:given-name>
                  <ce:surname>Wu</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0015">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523418310341-41382c590039811b6391093094f045b1">
                  <ce:given-name>Hong</ce:given-name>
                  <ce:surname>Bu</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0020">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523418310341-7f00d91b78a199adf55f3f0d1c4b735c">
                  <ce:given-name>Jinpei</ce:given-name>
                  <ce:surname>Zhou</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0025">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor1" id="crosref0030">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au5" orcid="0000-0002-1960-4598" author-id="S0223523418310341-0a3d6faeffd234e3d12d1132d96d80b2">
                  <ce:given-name>Huibin</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0035">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor2" id="crosref0040">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523418310341-8013a5f1b0a5365058cd695a3d8ce1cd">
                  <ce:label>a</ce:label>
                  <ce:textfn>Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Center of Drug Discovery</sa:organization>
                     <sa:organization>State Key Laboratory of Natural Medicines</sa:organization>
                     <sa:organization>China Pharmaceutical University</sa:organization>
                     <sa:address-line>24 Tongjiaxiang</sa:address-line>
                     <sa:city>Nanjing</sa:city>
                     <sa:postal-code>210009</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523418310341-ce3c7a91b55fbb45d77bc20d2845a081">
                  <ce:label>b</ce:label>
                  <ce:textfn>Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Medicinal Chemistry</sa:organization>
                     <sa:organization>China Pharmaceutical University</sa:organization>
                     <sa:address-line>24 Tongjiaxiang</sa:address-line>
                     <sa:city>Nanjing</sa:city>
                     <sa:postal-code>210009</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="17" month="10" year="2018"/></ce:date-received>
            <ce:date-revised day="27" month="11" year="2018"/></ce:date-revised>
            <ce:date-accepted day="29" month="11" year="2018"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">With the rise of immuno-oncology, small-molecule modulators targeting immune system and inflammatory processes are becoming a research hotspot. This work mainly focuses on key kinases acting as central nodes in immune signaling pathways. Although over thirty small-molecule kinase inhibitors have been approved by FDA for the treatment of various cancers, only a few are associated with immuno-oncology. With the going deep of the research work, more and more immunity protein kinase inhibitors are approved for clinical trials to treat solid tumors and hematologic malignancies by FDA, which remain good prospects. Meanwhile, in-depth understanding of biological function of immunity protein kinases in immune system is pushing the field forward. This article focuses on the development of safe and effective small-molecule immunity protein kinase inhibitors and further work needs to keep the promises of these inhibitors for patients’ welfare.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text role="short" id="alttext0010">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418310341/fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Immuno-oncology</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Immunity protein kinases</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Small-molecules inhibitors</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0025" view="all">In normal immune system, antigens are presented to naive T cells and lead to the activation, differentiation and expansion of T cells. Activated T cells secrete cytokines to attract and activate macrophages, neutrophils and natural killer (NK) cells in the immune system. However, once immune tolerance or unresponsiveness to self-antigens is collapsed, chronic inflammatory state can maintain and bring about local and systemic pernicious effects on host cells and tissues [<ce:cross-ref refid="bib1" id="crosref0045">1</ce:cross-ref>]. More importantly, abnormalities associated with inflammation can lead to and accelerate the development of cancers. Because various cell types and signaling pathways are involved in the inflammation-related cancers, there are several vital control points and numerous potential drug targets [<ce:cross-ref refid="bib2" id="crosref0050">2</ce:cross-ref>]. Among them, immunity protein kinases function as critical points of signaling pathways and fit to be targeted by small-molecular modulators.</ce:para>
                  <ce:para id="p0030" view="all">Nowadays, over thirty small-molecule kinase inhibitors are approved by FDA and available for use outside of inflammatory diseases. Deregulated activity of kinase signaling pathways is a hallmark of cancer and inflammation and targeting kinase enzymatic activity has become an effective therapy for various cancers. The chemokines, cytokines and growth factors expressed by these pathways play an important role as mediators of oncogenesis, tumor progression and mechanisms of therapeutic resistance. Moreover, these tumor-derived chemoattractants often invade the tumor location and contribute to the formation of immunosuppressive tumor microenvironment [<ce:cross-ref refid="bib3" id="crosref0055">3</ce:cross-ref>,<ce:cross-ref refid="bib4" id="crosref0060">4</ce:cross-ref>].</ce:para>
                  <ce:para id="p0035" view="all">So far, the research and development of small-molecular inhibitors of these immunity protein kinases which are being profiled in kinome-wide screens and evaluated in various experimental animal models of inflammation and cancer before entering the clinical trials, have been exploded for many years [<ce:cross-ref refid="bib5" id="crosref0065">5</ce:cross-ref>]. Considering that the specificity, activity, bioavailability and safety of the small-molecule kinases inhibitor are sufficiently satisfactory, it now becomes feasible that the development of immunity protein kinase inhibitors will pave a new way for the treatment of cancer. This review provides a brief introduction into recent advances related to some immunity protein kinases for immuno-oncology and their small-molecule inhibitors.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Small molecules targeting the immunity protein kinases</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">MNK inhibitors</ce:section-title>
                     <ce:para id="p0040" view="all">MNKs, mitogen-activated protein kinase (MAPK) interacting kinases, belong to serine/threonine protein kinase family. Both of MNK genes, MNK1 and MNK2, encode two protein isoforms: MNK1a/MNK1b and MNK2a/MNK2b through alternative splicing events. The longer a-isoforms, MNK1a and MNK2a containing a MAPK-binding site in the C-terminal regions can be activated and phosphorylated by ERK and p38 MAPK, and the b-isoforms lack this MAPK-binding site [<ce:cross-ref refid="bib6" id="crosref0070">6</ce:cross-ref>].</ce:para>
                     <ce:para id="p0045" view="all">Located at the meeting-point of several oncogenic and immune signaling pathways (RAS, PI3K/mTOR, p38-MAPK pathways and toll-like receptors), MNK-eIF4E axis has come into sharper focus in recent years due to its vital roles in integrating signals into the initiation of protein translation and regulating multiple critical processes of tumor cell biology and immune system. Remarkably, MNKs are the only kinases that phosphorylate eIF4E at the conserved serine 209 exclusively. As the proto-oncogenic limiting factor, phosphorylated eIF4E is primarily responsible for the formation of eIF4F complex, which can bind the 7-methylguanosine cap structure and regulate the translation of mRNA. So, MNK-eIF4E signal pathway can influence the expression of tumor-associated proteins (c-Myc, cyclins D1, cyclins D3 and Mcl-1), checkpoint receptors (PD-1, TIM3 and LAG3) and tumor-associated cytokines (NF-κB, TNF-α and Type I/II IFNs) (<ce:cross-ref refid="fig1" id="crosref0075">Fig. 1</ce:cross-ref>
                        <ce:float-anchor refid="fig1"/></ce:float-anchor>) [<ce:cross-refs refid="bib7 bib8 bib9 bib10 bib11" id="crosrefs0010">7–11</ce:cross-refs>]. Other key effector proteins, SPRY2, HNRNPA1, PSF and CPLA2, are reported as the substrates of MNKs [<ce:cross-refs refid="bib12 bib13 bib14 bib15" id="crosrefs0015">12–15</ce:cross-refs>]. More importantly, though MNKs are vital to the development of cancers and drug resistance of cancer therapeutics, MNK double knock-out mice and cells are viable and developed normally [<ce:cross-refs refid="bib16 bib17 bib18" id="crosrefs0020">16–18</ce:cross-refs>]. So, targeting MNKs may present an attractive therapeutic strategy for immuno-oncology.</ce:para>
                     <ce:para id="p0050" view="all">Today, several kinds of MNK inhibitors are developed for the treatment of oncology, autoimmune and inflammatory disorders, and three of them (<ce:bold>BAY 1143269</ce:bold>, <ce:bold>eFT508</ce:bold> and <ce:bold>ETC-206</ce:bold>) developed by Bayer AG, Effector Therapeutics and Experimental Therapeutics Centre respectively have entered trials for a number of hematological malignancies and solid tumors (<ce:cross-ref refid="fig2" id="crosref0080">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0055" view="all">
                        <ce:bold>CGP57380</ce:bold> is the first synthetic small-molecule MNK inhibitor, and it blocks MNK1 and MNK2 with IC<ce:inf loc="post">50</ce:inf> values of 0.87 μM and 1.6 μM [<ce:cross-ref refid="bib19" id="crosref0085">19</ce:cross-ref>]. As a tool compound, <ce:bold>CGP57380</ce:bold> has been used in various pharmacological and mechanistic studies. The anti-proliferative activity of <ce:bold>CGP57380</ce:bold> against breast cancer cells is primarily cytostatic through inhibiting the cyclin D1 synthesis rather than cytotoxic [<ce:cross-ref refid="bib20" id="crosref0090">20</ce:cross-ref>]. <ce:bold>CGP57380</ce:bold> can induce a significant decrease in XIAP protein expression and NF-κB signal and inhibit inflammatory breast cancer cell dissemination in a dorsal skin fold window chamber murine model [<ce:cross-ref refid="bib21" id="crosref0095">21</ce:cross-ref>]. Because that pyrazolo[3,4-d]pyrimidine, the scaffold of <ce:bold>CGP57380</ce:bold>, lacks the specific interaction with the conserved ATP-binding pocket of MNKs, the further modification of <ce:bold>CGP57380</ce:bold> have not led to the new compounds with better activity and selectivity [<ce:cross-ref refid="bib22" id="crosref0100">22</ce:cross-ref>,<ce:cross-ref refid="bib23" id="crosref0105">23</ce:cross-ref>].</ce:para>
                     <ce:para id="p0060" view="all">
                        <ce:bold>BAY 1143269</ce:bold> (the structure is still undisclosed) is a selective MNK1 inhibitor identified by Bayer AG through high-throughput screening, which inhibited the potency of MNK1 with IC<ce:inf loc="post">50</ce:inf> of 40 nM and showed the moderate activity against MNK2 and PIM1 with IC<ce:inf loc="post">50</ce:inf> of 904 nM and 518 nM, respectively [<ce:cross-ref refid="bib24" id="crosref0110">24</ce:cross-ref>,<ce:cross-ref refid="bib25" id="crosref0115">25</ce:cross-ref>]. <ce:bold>BAY 1143269</ce:bold> not only results in cell cycle deregulation and apoptosis induction, but also suppresses the expression of pro-inflammatory and pro-tumorigenic cytokines [<ce:cross-ref refid="bib26" id="crosref0120">26</ce:cross-ref>]. Single administration of <ce:bold>BAY 1143269</ce:bold> exhibited significant anti-tumor activity in non-small-cell lung cancer (NSCLC), colorectal cancer and melanoma xenograft models, and combinational therapy with <ce:bold>Docetaxel</ce:bold> or <ce:bold>Pemetrexed</ce:bold> showed additive potency in cell line-derived or human-derived NSCLC xenograft models [<ce:cross-ref refid="bib26" id="crosref0125">26</ce:cross-ref>,<ce:cross-ref refid="bib27" id="crosref0130">27</ce:cross-ref>]. Phase I clinical trials of <ce:bold>BAY 1143269</ce:bold> started in May 2015 (NCT02439346, combination with <ce:bold>Docetaxel</ce:bold>), but there has been few progress in the years that followed.</ce:para>
                     <ce:para id="p0065" view="all">
                        <ce:bold>eFT-508</ce:bold> was developed by Effector Therapeutics as the second clinical MNK inhibitor, which showed dual inhibitory activity of MNK1 and MNK2. <ce:bold>eFT-508</ce:bold> can down-regulate the expression of immune checkpoint (PD-1, TIM3, 4-1BB and LAG3) and pro-inflammatory/immunosuppressive cytokines (IL-6, IL-8, IL-10, TNF-α and CXCL-10). Furthermore, <ce:bold>eFT-508</ce:bold> can induce T cell activation and proliferation, block induced-Treg differentiation and promote T cell central memory pool formation and cytotoxic potency of effector T cell [<ce:cross-ref refid="bib7" id="crosref0135">7</ce:cross-ref>,<ce:cross-ref refid="bib28" id="crosref0140">28</ce:cross-ref>]. <ce:bold>eFT-508</ce:bold> showed anti-tumor potency and restored anti-tumor immunity in various tumor xenograft models including MYD88-mutant diffuse large B-cell lymphoma (DLBCL) with a low dose of 1 mg/kg. In CT-26 allografts, <ce:bold>eFT-508</ce:bold> can enhance the anti-tumor activity of PD-1 monoclonal antibody, and re-challenge experiment of CT-26 allografts which have been treated with <ce:bold>eFT-508</ce:bold> exhibited great regression of tumor again in the absence of any further treatment [<ce:cross-ref refid="bib7" id="crosref0145">7</ce:cross-ref>]. <ce:bold>eFT-508</ce:bold> has progressed into Phase I/II as a single administration in lymphoma (NCT02937675), liver cancer/metastatic NSCLC (NCT02605083) and triple negative breast cancer/hepatocellular carcinoma (NCT03318562), and as a single administration or combinational therapy with avelumab in microsatellite stable relapsed or refractory colorectal cancer (NCT03258398). Clinical data from Phase I trial of standalone <ce:bold>eFT-508</ce:bold> suggested that this inhibitor has acceptable safety, relatively well tolerability profile and preliminary and satisfactory therapeutic benefits [<ce:cross-ref refid="bib29" id="crosref0150">29</ce:cross-ref>]. In February 2017, <ce:bold>eFT-508</ce:bold> was granted Orphan Drug designation by FDA for the treatment of DLBCL. <ce:bold>ETC-206</ce:bold>, a selective small-molecule inhibitor targeting MNK1/2, exhibited synergistic activity of inhibiting tumor growth combined with Dasatinib in blast crisis chronic myelocytic leukemia (BC-CML) mouse xenograft model [<ce:cross-ref refid="bib30" id="crosref0155">30</ce:cross-ref>]. <ce:bold>ETC-206</ce:bold> entered into Phase I clinical trials for the treatment of advanced hematological malignancies (NCT03414450, combined with <ce:bold>Dasatinib</ce:bold>) in January 2018 and exhibited well safety and toleration without clinically relevant symptoms in the early clinical trials (<ce:cross-ref refid="tbl1" id="crosref0160">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>) [<ce:cross-ref refid="bib31" id="crosref0165">31</ce:cross-ref>].</ce:para>
                     <ce:para id="p0070" view="all">According to the available data of clinical trials, the median half-life of <ce:bold>eFT-508</ce:bold> and <ce:bold>ETC-206</ce:bold> were 11 h and 25 h respectively. 200 mg dose of <ce:bold>eFT-508</ce:bold> inhibits the p-eIF4E of patient peripheral blood mononuclear cells by 85% during a 24 h period, and 20 mg of <ce:bold>ETC-206</ce:bold> achieves a medium inhibition of 28% at 24 h. Clinical trial of <ce:bold>BAY 1143269</ce:bold> as a combination therapy with docetaxel in NSCLC was terminated due to project prioritization. Combined deficiency of MNK1 and MNK2 can prevent phosphorylation of eIF4E fully and delay tumorigenesis more effectively, indicating that there is overlap in their function despite minor differences observed in their activity and regulation [<ce:cross-ref refid="bib18" id="crosref0175">18</ce:cross-ref>]. Compared with <ce:bold>eFT-508</ce:bold> and <ce:bold>ETC-206</ce:bold>, <ce:bold>BAY 1143269</ce:bold> is a relatively moderate and selective MNK1 inhibitor, which may lead to the discontinuation of clinical trial. In this case, dual MNK1/2 inhibitors have a better perspective than MNK1 or MNK2 selective inhibitors in the future. All previously reported MNK inhibitors including <ce:bold>eFT-508</ce:bold> showed unsatisfactory inhibitory potency against tumor cells <ce:italic>in vitro</ce:italic> [<ce:cross-ref refid="bib9" id="crosref0180">9</ce:cross-ref>,<ce:cross-ref refid="bib26" id="crosref0185">26</ce:cross-ref>], demonstrating that anti-tumor activity of these inhibitors depends on immune system in all likelihood.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">PI3Kδ and PI3Kγ</ce:section-title>
                     <ce:para id="p0075" view="all">PI3Ks are divided into three classes on the basis of their function and sequence homology [<ce:cross-ref refid="bib32" id="crosref0190">32</ce:cross-ref>]. Class I PI3Ks, the focus of pharmaceutical research, are further divided into two classes, class IA and class IB according to signaling pathways and regulatory proteins. The class IA are composed of PI3Kα, PI3Kβ and PI3Kδ, activated by receptor tyrosine kinases (RTKs), and the class IB comprises only one, PI3Kγ, signaling through G-protein coupled receptors (GPCRs). PI3Kα and PI3Kβ are expressed ubiquitously, but PI3Kδ and PI3Kγ only exist in leukocytes subtypes abundantly [<ce:cross-ref refid="bib33" id="crosref0195">33</ce:cross-ref>].</ce:para>
                     <ce:para id="p0080" view="all">Cytosolic PI3Ks can transform phosphatidylinositol(4,5)bisphosphate (PIP2) into phosphatidylinositol(3,4,5)trisphosphate PIP3 via phosphorylating 3′-hydroxyl position of the inositol ring [<ce:cross-ref refid="bib34" id="crosref0200">34</ce:cross-ref>]. As the second messengers and membrane anchor site, PIP3 recruits multiple protein kinases containing pleckstrin homology (PH) domains (such as AKT, PDK1, BTK and ETK) together to the cytoplasmic side of cell membrane and plays an important role in various cellular processes including membrane trafficking and transport, cytoskeleton organization and downstream signaling pathway (<ce:cross-ref refid="fig3" id="crosref0205">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>) [<ce:cross-ref refid="bib32" id="crosref0210">32</ce:cross-ref>].</ce:para>
                     <ce:para id="p0085" view="all">At the present time, most studies of oncogenic mutations focus on pan-PI3K inhibitors. But PI3Kδ and PI3Kγ are expected to be the better targets with lower toxic therapy, because these two kinases are primarily expressed in leukocytes and important to the immunomodulatory effects in tumor microenvironment [<ce:cross-ref refid="bib32" id="crosref0215">32</ce:cross-ref>,<ce:cross-ref refid="bib35" id="crosref0220">35</ce:cross-ref>,<ce:cross-ref refid="bib36" id="crosref0225">36</ce:cross-ref>]. In tumors, diverse mechanisms promote the recruitment and expansion of Tregs to block effector T cell responses [<ce:cross-ref refid="bib37" id="crosref0230">37</ce:cross-ref>,<ce:cross-ref refid="bib38" id="crosref0235">38</ce:cross-ref>]. PI3Kδ can not only regulate the function of Tregs, but also is crucial for the migration and recruitment of Tregs [<ce:cross-ref refid="bib38" id="crosref0240">38</ce:cross-ref>]. PI3Kδ inhibitor can restore anti-tumor immunity by dampening the function of Tregs and MDSCs, and inhibition of PI3Kδ can protect mice against various hematological malignancies and solid tumors [<ce:cross-ref refid="bib36" id="crosref0245">36</ce:cross-ref>]. At the same time, PI3Kδ-KO mice exhibited stronger resistance to re-challenge of secondary tumor administration [<ce:cross-ref refid="bib35" id="crosref0250">35</ce:cross-ref>].</ce:para>
                     <ce:para id="p0090" view="all">PI3Kγ is sufficient and necessary to the activation of α4β1, a single integrin which stimulates the immunosuppressive polarization of MDSCs and tumor-associated macrophages and promotes myeloid cell to trafficking tumors. Inhibition of PI3Kγ or α4β1 also can reduce the accumulation of infiltrating CD4<ce:sup loc="post">+</ce:sup>/CD8<ce:sup loc="post">+</ce:sup> T cells into the tumor microenvironment with the increasing production of immunostimulatory cytokines (IL-12 and IFNγ), indicating the formation of a stronger anti-tumor microenvironment [<ce:cross-ref refid="bib39" id="crosref0255">39</ce:cross-ref>]. At the same time, development and invasion of tumor are dampened substantially in PI3Kγ-KO mice or WT mice transplanted with PI3Kγ-KO bone marrow cell, but not in PI3Kγ-KO mice or WT mice transplanted with WT bone marrow cell [<ce:cross-ref refid="bib4" id="crosref0260">4</ce:cross-ref>]. PI3Kγ signaling in macrophages blocks the activation of NF-κB and stimulates the activity of C/EBPβ, which promotes immunosuppression in inflammation and tumor growth. Conversely, inhibition of PI3Kγ in macrophage can stimulate and extend NF-κB activation and block the potency of C/EBPβ, which restores the activity and cytotoxicity of CD8<ce:sup loc="post">+</ce:sup> T cell by promoting the immunostimulatory transcriptional program [<ce:cross-ref refid="bib40" id="crosref0265">40</ce:cross-ref>].</ce:para>
                     <ce:para id="p0095" view="all">With the confirmation of various PI3K isoforms, inhibitors for one certain isoform with high selectivity have been developed. Many companies, including Gilead, Incyte, Takeda and UCSF, have been active in developing PI3Kδ selective inhibitor for many years. <ce:bold>Idelalisib</ce:bold> (Gilead) was approved by FDA for the treatment of patients with relapsed chronic lymphocytic leukemia and relapsed follicular B-cell non Hodgkin lymphoma in 2014 [<ce:cross-ref refid="bib41" id="crosref0270">41</ce:cross-ref>]. Besides this, there are some selective inhibitors of PI3Kδ in the late-stage clinical trials. <ce:bold>Umbralisib</ce:bold> is developed by TG Therapeutics in clinical Phase III trials for the treatment of chronic lymphocytic leukemia and diffuse large B cell lymphoma (NCT03364231, NCT03379051, NCT03283137, etc.). <ce:bold>Dezapelisib</ce:bold> (Incyte) is in clinical Phase I/II trials for patients with B-cell malignancies (NCT01905813) and refractory Hodgkin lymphoma/recurrent adult Hodgkin lymphoma (NCT02456675). Treatment of <ce:bold>Dezapelisib</ce:bold> can reduce the production of TNF-β and MIP-1, which can impact immune function directly or indirectly. <ce:bold>Dezapelisib</ce:bold> is effective for treating Hodgkin lymphoma through inhibiting TNF-β dependent survival of stroma cells and blocking CCR5-mediated chemokines and cytokines of stroma cells into the tumor mass [<ce:cross-ref refid="bib42" id="crosref0275">42</ce:cross-ref>]. <ce:bold>PI-3065</ce:bold>, a highly selective PI3Kδ inhibitor with 72 to >1800-fold selectivity against other PI3K isoforms, contributes to reduced incidence of growth, metastasis and other pathology in pancreatic ductal adenocarcinoma and breast carcinoma model. Interestingly, the expression of PI3Kδ in 4T1 cell is undetectable and <ce:bold>PI-3065</ce:bold> can not inhibit the growth of 4T1 cell <ce:italic>in vitro</ce:italic> (<ce:cross-ref refid="fig4" id="crosref0280">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>) [<ce:cross-ref refid="bib36" id="crosref0285">36</ce:cross-ref>].</ce:para>
                     <ce:para id="p0100" view="all">Selective PI3Kγ inhibitors also have a promising prospect and are of great interest to pharmaceutical companies and research institutions. <ce:bold>IPI-549</ce:bold> (Infinity) is a highly potent and selective PI3Kγ inhibitor with 58–282-fold selectivity against other PI3K isoforms, which is in Phase I/Ib trials for advanced solid tumors (NCT02637531) [<ce:cross-ref refid="bib43" id="crosref0290">43</ce:cross-ref>]. In multiple tumor models, <ce:bold>IPI-549</ce:bold> can improve anti-tumor immunity by decreasing immune suppressive myeloid cells and increasing CD8<ce:sup loc="post">+</ce:sup> T cells. The results of immune-deficient or CD8<ce:sup loc="post">+</ce:sup> T cell depleted xenograft model also demonstrate that the anti-tumor activity of <ce:bold>IPI-549</ce:bold> depends on immune system regulated by T cells. Compared with monotherapy, the combined therapies of <ce:bold>IPI-549</ce:bold> and immune checkpoint inhibitors show better activity in various pre-clinical models [<ce:cross-ref refid="bib44" id="crosref0295">44</ce:cross-ref>]. Other PI3Kγ inhibitors like <ce:bold>TG100-115</ce:bold> and <ce:bold>AS-605240</ce:bold> block growth, metastasis, and inflammation of implanted and spontaneous tumors by targeting immunosuppressive myeloid cells (<ce:cross-ref refid="fig5" id="crosref0300">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>) (<ce:cross-ref refid="tbl2" id="crosref0785">Table 2</ce:cross-ref>
                        <ce:float-anchor refid="tbl2"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0105" view="all">PI3K-δ inhibitors target proliferation and survival of malignant B-cell leukemia directly, and PI3K-γ inhibitors block the differentiation and migration of CD4<ce:sup loc="post">+</ce:sup> T cells and tumor-associated macrophages in the tumor microenvironment [<ce:cross-ref refid="bib40" id="crosref0305">40</ce:cross-ref>,<ce:cross-ref refid="bib45" id="crosref0310">45</ce:cross-ref>,<ce:cross-ref refid="bib46" id="crosref0315">46</ce:cross-ref>]. Given complementary function of PI3Kδ and PI3Kγ in supporting tumor growth and survival, dual inhibitors have a broader prospect and more benefits. <ce:bold>Duvelisib</ce:bold>, a dual inhibitor of PI3Kγ and PI3Kδ, has launched in 2018 for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and relapsed or refractory follicular lymphoma [<ce:cross-ref refid="bib47" id="crosref0320">47</ce:cross-ref>]. The preclinical model shows that <ce:bold>Duvelisib</ce:bold> can transform the immunosuppressive M2-like tumor-associated macrophages to the inflammatory M1-like tumor-associated macrophages and the early clinical data indicate that <ce:bold>Duvelisib</ce:bold> can reduce the production of key cytokines and chemokines expressed by malignant B cells and tumor-supporting myeloid cells (<ce:cross-ref refid="fig5" id="crosref0325">Fig. 5</ce:cross-ref>) [<ce:cross-refs refid="bib47 bib48 bib49" id="crosrefs0025">47–49</ce:cross-refs>].</ce:para>
                     <ce:para id="p0110" view="all">
                        <ce:bold>Idelalisib</ce:bold>, launched into market as the first-in-class PI3K-isoform selective inhibitor, is significantly effective but received a black box warning for severe diarrhea or colitis, pneumonitis, hepatotoxicity and intestinal perforation [<ce:cross-ref refid="bib50" id="crosref0330">50</ce:cross-ref>]. It is reported that PI3Kγ is expressed in cardiomyocytes and PI3Kγ-KO mice fail to deal with cardiac distress [<ce:cross-ref refid="bib51" id="crosref0335">51</ce:cross-ref>,<ce:cross-ref refid="bib52" id="crosref0340">52</ce:cross-ref>]. But, in Phase I/Ib clinical trials of <ce:bold>IPI549,</ce:bold> no dose-limiting toxicities (DLTs) are observed and most of treatment-emergent adverse events are low-grade. What's more, early clinical data suggest that adverse event profile of <ce:bold>Duvelisib</ce:bold> was manageable and most of treatment-emergent adverse events also present as low-grade events. Phase III clinical trials of <ce:bold>Duvelisib</ce:bold> indicate that oral monotherapy of <ce:bold>Duvelisib</ce:bold> improves Progression-Free Survival (PFS) significantly versus the approved standard of treatment of <ce:bold>Atumumab</ce:bold>, along with a well characterized and controlled safety profile. <ce:bold>Duvelisib</ce:bold> also increases Overall Response Rate (ORR) greatly and reduces lymph node burden in the majority of patients significantly. So, developing dual PI3Kδ/γ inhibitors is expected to be more potential for the treatment of solid tumor and hematologic malignancy.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">TYK2</ce:section-title>
                     <ce:para id="p0115" view="all">Non-receptor tyrosine kinase 2 (TYK2) belongs to the Janus kinase (JAK) family, which contains the other three members, JAK1, JAK2 and JAK3. JAK1, JAK2 and TYK2 are broadly activated by different cytokines in various cell types, while JAK3 is limited to primarily hematopoietic cells. JAKs are activated upon ligand binding to the extracellular domain of receptor complex. Then, JAKs can phosphorylate receptor chains, which become docking sites for STATs. Recruited STAT homo- and/or heterodimers are phosphorylated and subsequently translocate to the nucleus, which can induce transcription of target genes [<ce:cross-ref refid="bib53" id="crosref0345">53</ce:cross-ref>]. JAKs are linked with different cytokine receptors and function either alone or in combination with other JAK members. Interestingly, TYK2 is activated in combination with JAK1 and/or JAK2 but not with JAK3 (<ce:cross-ref refid="fig6" id="crosref0350">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>) [<ce:cross-ref refid="bib54" id="crosref0355">54</ce:cross-ref>].</ce:para>
                     <ce:para id="p0120" view="all">As the first isoform of JAKs related to cytokine response genetically, TYK2 is associated with many receptor pathways including IL-10 receptor β, IL-12 receptor β1, IL-13 receptor α1 and IFN α receptor 1 [<ce:cross-ref refid="bib55" id="crosref0360">55</ce:cross-ref>,<ce:cross-ref refid="bib56" id="crosref0365">56</ce:cross-ref>]. Though the lack of JAK1 and JAK2 is lethal and the lack of JAK3 is linked to the severe combined immunodeficiency, deficiency of TYK2 would not lead to pathologic abnormalities under conventional living conditions [<ce:cross-refs refid="bib57 bib58 bib59 bib60" id="crosrefs0030">57–60</ce:cross-refs>]. Genome-wide association studies exhibit that TYK2 is closely associated with the host responses to infectious agents and multiple autoimmune or autoinflammatory diseases [<ce:cross-ref refid="bib61" id="crosref0370">61</ce:cross-ref>]. And the polymorphisms of TYK2 emerged in recent years is related to systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, type I diabetes and ulcerative colitis [<ce:cross-refs refid="bib62 bib63 bib64 bib65" id="crosrefs0035">62–65</ce:cross-refs>].</ce:para>
                     <ce:para id="p0125" view="all">The important role of TYK2 in tumor immunosurveillance has already been demonstrated for many years. Firstly, TYK2 is overexpressed in several cancer cell lines. Inhibiting TYK2 can reduce invasiveness and metastasis of malignant cells [<ce:cross-ref refid="bib66" id="crosref0375">66</ce:cross-ref>]. TYK2 functions downstream of growth factor receptors hyperactivated in cancer [<ce:cross-ref refid="bib67" id="crosref0380">67</ce:cross-ref>]. Unfortunately, suppression of TYK2 can induce the development of hematological malignancies through damaging the cytotoxicity of NK and CD8<ce:sup loc="post">+</ce:sup> T cells in mice models [<ce:cross-ref refid="bib68" id="crosref0385">68</ce:cross-ref>]. And TYK2 is indispensable in the immunosurveillance of adenocarcinoma and lymphoma cells. However, NK cell-mediated immunosurveillance and cytotoxicity of NK and T cells are partly or fully independent of the catalytic activity of TYK2, which reveals that TYK2 inhibitors for cancer therapy would not break the NK cell-mediated tumor surveillance and are suitable for cancer therapy [<ce:cross-ref refid="bib69" id="crosref0390">69</ce:cross-ref>].</ce:para>
                     <ce:para id="p0130" view="all">Though the importance of cell intrinsic TYK2 in oncogenesis has been intensively reported for many years, the only TYK2 inhibitor in clinical trials, <ce:bold>BMS-986165</ce:bold> (Bristol-Myers Squibb), is developed for the patients with severe psoriasis and systemic lupus erythematosus excluding any cancers (<ce:cross-ref refid="fig7" id="crosref0395">Fig. 7</ce:cross-ref>
                        <ce:float-anchor refid="fig7"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0135" view="all">
                        <ce:bold>NDI-031301</ce:bold> (the structure is still undisclosed) is developed by Nimbus as a highly selective TYK2 inhibitor. It shows significant anti-leukaemic activity against human T-cell acute lymphoblastic leukemia cell lines. Preclinical studies exhibit that <ce:bold>NDI-031301</ce:bold> potently inhibits cytokine signaling of immune cell and demonstrates promising efficacy in mouse models of psoriasis. In xenograft model of KOPT-K1 cells, <ce:bold>NDI-031301</ce:bold> is well tolerated without any side effects and body weight loss. As a result, <ce:bold>NDI-031301</ce:bold> can block tumor progression and increase overall survival greatly [<ce:cross-ref refid="bib70" id="crosref0400">70</ce:cross-ref>]. In a hypersensitivity mouse model induced by methylated-BSA, <ce:bold>NDI-031301</ce:bold> decreases Th1 and Th17 cytokines in the inflamed paws by up to 50%. In IL-23-induced mouse psoriasis model, <ce:bold>NDI-031301</ce:bold> reduced skin inflammation with more than 76% inhibition of ear swelling [<ce:cross-ref refid="bib71" id="crosref0405">71</ce:cross-ref>]. Sareum also reports a potent TYK2 inhibitor, <ce:bold>SAR-20347</ce:bold> which reduces disease severity in a preclinical psoriasis model and blocks the growth of tumor in T-cell acute lymphoblastic leukemia models significantly (<ce:cross-ref refid="fig7" id="crosref0410">Fig. 7</ce:cross-ref>) [<ce:cross-ref refid="bib72" id="crosref0415">72</ce:cross-ref>].</ce:para>
                     <ce:para id="p0140" view="all">Nowadays, pan-JAK inhibitors have been under clinical trials for use in cancer therapy. Though the exact role of TYK2 in oncogenesis and tumor progression is unclear, TYK2 inhibitors can reduce the invasiveness of tumor cells and suppress the development in T-cell acute lymphoblastic leukemia models. So, TYK2 inhibitors might also have beneficial effects for cancer treatment.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0055">TGFBR1/ALK5</ce:section-title>
                     <ce:para id="p0145" view="all">Transforming growth factor-β (TGF-β) belonging to TGF-β superfamily consist of TGF-β1, TGF-β2 and TGF-β3. TGF-β pathway is essential for cancer development because of its prominent roles in the regulation of cellular processes, production of extracellular matrix, epithelial−mesenchymal transition and immune suppression [<ce:cross-ref refid="bib73" id="crosref0420">73</ce:cross-ref>]. TGFβ1 is expressed in invasive breast cancer related with markers of tumor progression, such as metastasis, extracellular matrix deposition and the infiltration of immune cells [<ce:cross-ref refid="bib74" id="crosref0425">74</ce:cross-ref>]. As a pivotal regulator, TGF-β signaling can transform the epithelial phenotype and the stromal environment which are important for tumor progression. Therefore, blockade of TGF-β signaling pathway is an attractive target for immuno-oncology.</ce:para>
                     <ce:para id="p0150" view="all">Secreted as inactive homodimer, TGFβ1, TGFβ2 and TGFβ3 ligands can bind with TGFβ-binding proteins, which promote extracellular signal transmission. After activated, these ligands bind with TGFBR2 (TGFβ receptor type 2), which recruits and phosphorylates of TGFBR1 (also known as ALK5, activin receptor-like kinase 5) [<ce:cross-ref refid="bib75" id="crosref0430">75</ce:cross-ref>,<ce:cross-ref refid="bib76" id="crosref0435">76</ce:cross-ref>]. In the downstream signaling, the transcriptional regulators SMAD family member SMAD2 or SMAD3 are phosphorylated and form heterozygosis with SMAD4 [<ce:cross-ref refid="bib77" id="crosref0440">77</ce:cross-ref>,<ce:cross-ref refid="bib78" id="crosref0445">78</ce:cross-ref>]. Through binding with various DNA-binding cofactors and regulators, the nuclear-localized complex activates the transcription of TGF-β target genes involved in cell proliferation, differentiation, migration and apoptosis (<ce:cross-ref refid="fig8" id="crosref0450">Fig. 8</ce:cross-ref>
                        <ce:float-anchor refid="fig8"/></ce:float-anchor>) [<ce:cross-refs refid="bib79 bib80 bib81" id="crosrefs0040">79–81</ce:cross-refs>].</ce:para>
                     <ce:para id="p0155" view="all">Aberrant overexpression of TGF-β and its receptors and hyperactivation of downstream signaling are closely associated with various human diseases, including cancer, tissue fibrosis, inflammation and autoimmunity [<ce:cross-ref refid="bib81" id="crosref0455">81</ce:cross-ref>,<ce:cross-ref refid="bib82" id="crosref0460">82</ce:cross-ref>]. Through SMAD-dependent expression of matrix metalloproteinases, dysfunction of TGF-β signaling in mammary tumor cells can promote the angiogenesis and tumor cell invasion [<ce:cross-ref refid="bib83" id="crosref0465">83</ce:cross-ref>]. In the malignant epithelium of tumor microenvironment, TGF-β signaling can influence the regulation of miRNA, which is aberrantly expressed in various cancers and is closely associated with pro-tumorigenic and anti-tumorigenic function [<ce:cross-ref refid="bib84" id="crosref0470">84</ce:cross-ref>]. Through the activation of TGF-β signaling or the treatment of cancer cells with TGF-β, numerous gene targets conserved in various cancers are identified. Importantly, many of these targets play an important role in the changes of tumor microenvironment. For example, TGF-β in epithelial cells induces the expression of numerous ECM genes, including COL1A1 (collagen type 1 α1)/COL4A1 (collagen type 4 α1), matrix modifying enzymes MMP2/MMP9 and LOXL4 (lysyl oxidase homologue 4) [<ce:cross-ref refid="bib85" id="crosref0475">85</ce:cross-ref>].</ce:para>
                     <ce:para id="p0160" view="all">And due to above-mentioned deregulation of TGF-β signaling in various diseases, the elements of this pathway have been investigated as potential drug targets for several different therapeutic uses, including the development of small-molecule inhibitors of the intracellular kinase domain of TGFBR1 for immuno-oncology. A lot of small-molecule TGFBR1 inhibitors have been developed, including <ce:bold>SB-431542</ce:bold>, <ce:bold>SD-208</ce:bold>, <ce:bold>IN-1130</ce:bold>, <ce:bold>Vactosertib</ce:bold> and <ce:bold>Galunisertib</ce:bold>. <ce:bold>Galunisertib</ce:bold> identified by Lilly is developed in Phase II/III trials for the treatment of patients with multiple cancers and exerts therapeutically immunostimulatory effects in several mouse tumor models [<ce:cross-refs refid="bib86 bib87 bib88" id="crosrefs0045">86–88</ce:cross-refs>]. <ce:bold>Galunisertib</ce:bold> can suppress the development of melanoma together with enhanced cytotoxic T lymphocyte. In xenograft model of melanoma, <ce:bold>Galunisertib</ce:bold> induces the ubiquitin-mediated degradation of SMAD4 mainly in CD8<ce:sup loc="post">+</ce:sup> T cells responses [<ce:cross-ref refid="bib88" id="crosref0480">88</ce:cross-ref>]. The preliminary results from Phase I trials indicate that administration of <ce:bold>Galunisertib</ce:bold> is well-tolerated. <ce:bold>Galunisertib</ce:bold> exhibits significantly antineoplastic effects and does not result in pharmacologically relevant cardiotoxicity (NCT02304419) [<ce:cross-refs refid="bib89 bib90 bib91 bib92" id="crosrefs0050">89–92</ce:cross-refs>]. <ce:bold>Vactosertib</ce:bold> (MedPacto) is the second TGFBR1 inhibitor developed into the clinical Phase I/II trials for the treatment of patients of myelodysplastic syndromes (NCT03074006) and solid tumor (NCT02160106). In the preclinical trials, <ce:bold>Vactosertib</ce:bold> is reported to inhibit TGF-β signaling pathway, cell migration, invasion and lung metastasis of breast cancer cells with the increasing survival of xenograft mice models [<ce:cross-ref refid="bib93" id="crosref0485">93</ce:cross-ref>]. Combined with tyrosine kinase inhibitors, <ce:bold>Vactosertib</ce:bold> significantly delays disease relapse and prolongs survival of chronic myelocytic leukemia mice [<ce:cross-ref refid="bib73" id="crosref0490">73</ce:cross-ref>,<ce:cross-ref refid="bib94" id="crosref0495">94</ce:cross-ref>]. What's more, <ce:bold>Vactosertib</ce:bold> can enhance cytotoxicity of T lymphocyte to block the development of melanoma <ce:italic>in vivo</ce:italic> [<ce:cross-ref refid="bib88" id="crosref0500">88</ce:cross-ref>]. Besides these, many preclinical investigations of other inhibitors have been initiated already. <ce:bold>SB-431542</ce:bold> (GlaxoSmithKline) not only inhibits the TGF-β-induced proliferation, invasion and angiogenesis of glioma cells, but also suppresses the transcription of fibronectin and collagen in renal carcinoma cells. <ce:bold>SB-431542</ce:bold> also improves the maturation of dendritic cells and the function of CD8<ce:sup loc="post">+</ce:sup> T cell [<ce:cross-ref refid="bib95" id="crosref0505">95</ce:cross-ref>,<ce:cross-ref refid="bib96" id="crosref0510">96</ce:cross-ref>]. <ce:bold>IN-1130</ce:bold>, a TGFBR1 inhibitor, can block cell mobility, invasion and epithelial−mesenchymal transition induced by TGF-β signal pathway. Moreover, <ce:bold>IN-1130</ce:bold> can inhibit the metastasis of breast cancer to lung <ce:italic>in vivo</ce:italic> and increase the survival of xenograft mice significantly [<ce:cross-ref refid="bib97" id="crosref0515">97</ce:cross-ref>]. <ce:bold>SD-208</ce:bold> can suppress the matrigel invasion of human melanoma cells <ce:italic>in vitro</ce:italic> and block human melanoma metastasis to bone <ce:italic>in vivo</ce:italic>. Although the survival of mice inoculated with 1205Lu melanoma cells is prolonged, <ce:bold>SD-208</ce:bold> can not suppress the tumor growth of this xenograft model (<ce:cross-ref refid="fig9" id="crosref0520">Fig. 9</ce:cross-ref>
                        <ce:float-anchor refid="fig9"/></ce:float-anchor>) [<ce:cross-ref refid="bib98" id="crosref0525">98</ce:cross-ref>].</ce:para>
                     <ce:para id="p0165" view="all">Despite there is a long-lasting interest in TGFBR1 inhibitor for cancer therapy, development of promising drug candidates and progress of preclinical and clinical trials have been rather slow [<ce:cross-ref refid="bib99" id="crosref0535">99</ce:cross-ref>]. It might be explained by the facts that TGFβ can regulate the immune system both positively and negatively and early TGFBR1 inhibitors show the potential myocardial toxicity [<ce:cross-ref refid="bib100" id="crosref0540">100</ce:cross-ref>]. But the new generation of inhibitors have exhibited the improved safety profile and progressed into clinical development.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.5" view="all">
                     <ce:label>2.5</ce:label>
                     <ce:section-title id="sectitle0060">PIM</ce:section-title>
                     <ce:para id="p0170" view="all">PIM kinases (Proviral insertion site of Moloney murine leukemia virus kinases) are composed of three serine/threonine protein kinases: PIM1, PIM2 and PIM3, which play the significant role in cell cycle progression and signal transduction. Unlike many other protein kinases, PIM kinases have a highly conserved kinase domain and need no phosphorylation for activation because they lack regulatory domain. And PIM kinases are regulated by the rates of transcription, translation, and degradation [<ce:cross-ref refid="bib101" id="crosref0545">101</ce:cross-ref>]. JAK-STATs signal pathways control the transcription of PIM kinases, and PIM kinases can regulate the JAK/STATs pathway negatively in turn through binding with SOC proteins (cytokine signaling suppressor) which inhibit JAK-dependent signaling [<ce:cross-ref refid="bib102" id="crosref0550">102</ce:cross-ref>] (<ce:cross-ref refid="fig10" id="crosref0790">Fig. 10</ce:cross-ref>
                        <ce:float-anchor refid="fig10"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0175" view="all">PIM kinases play a vital role in cellular metabolism, cell cycle progression and signal transduction. PIM kinases are constitutively active and function as key downstream effectors of some important signaling pathways, which depend on PIM kinases to accelerate tumorigenesis [<ce:cross-ref refid="bib103" id="crosref0555">103</ce:cross-ref>]. More importantly, overexpression and/or dysfunction of PIM kinases have been reported in the progression of various cancers. PIM1 is overexpressed in clinical individuals of hematological malignancies and solid tumors, including leukemia, lymphoma, oral cavity, bladder and prostatic adenocarcinoma cancers [<ce:cross-ref refid="bib104" id="crosref0560">104</ce:cross-ref>,<ce:cross-ref refid="bib105" id="crosref0565">105</ce:cross-ref>]. Expression of PIM3 is limited to solid tumors (melanoma, gastric cancers and pancreatic adenocarcinoma), whereas PIM2 is highly expressed in both hematological malignancies (acute lymphoblastic leukemia and acute myeloid leukemia) and solid tumors (adenocarcinoma and squamous cell carcinoma) [<ce:cross-ref refid="bib105" id="crosref0570">105</ce:cross-ref>]. PIM1 can phosphorylate two proteins, the ATP binding cassette (ABC) transporters P-glycoprotein and breast cancer resistance protein (BCRP), which are closely related to drug resistance of patients with acute myeloid leukemia and other cancers. And knockdown of PIM1 also shows the suppression of drug resistance mediated by the above proteins [<ce:cross-ref refid="bib106" id="crosref0575">106</ce:cross-ref>].</ce:para>
                     <ce:para id="p0180" view="all">The glycolysis metabolite lactate can make the tumor microenvironment acidic, which improves inherent resistance of cancer stem cells by promoting blebbishield-mediated transformation and inhibiting the function of immune cells such as T cells and iTregs. PIM1 and PIM2 can phosphorylate BAD to regulate glycolysis shift and act as an upstream regulator of immune response [<ce:cross-ref refid="bib107" id="crosref0580">107</ce:cross-ref>]. The stability of PIM2 is mediated by FoxP3 protein in Tregs and PIM2 can induce the maturation and differentiation of Tregs [<ce:cross-ref refid="bib108" id="crosref0585">108</ce:cross-ref>]. In preclinical models, T cells from PIM-2<ce:sup loc="post">−/−</ce:sup> donors are more activated with increased proliferation and express higher level of CXCR3 and IFN-γ. With higher expression of IFN-γ, TNF-α and Fas-ligand, PIM-2 knockdown mice control tumor growth more effectively compared with WT. Importantly, PIM-2 deficient CD8<ce:sup loc="post">+</ce:sup> T cells are more active in suppressing tumor growth than PIM1/3 deficient or WT CD8<ce:sup loc="post">+</ce:sup> T cells [<ce:cross-ref refid="bib109" id="crosref0590">109</ce:cross-ref>]. PIM3 can upregulate the expression of c-Myc by enhancing the translation of IRE, and the cooperation of PIM3 and c-Myc can block the activation of immune cells [<ce:cross-ref refid="bib110" id="crosref0595">110</ce:cross-ref>]. Inhibition of PIM1/3 could block the proliferation of CD4<ce:sup loc="post">+</ce:sup> T cells through inducing G0/G1 cell cycle arrest and the differentiation of CD4<ce:sup loc="post">+</ce:sup> T cells into effector T cells <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> [<ce:cross-ref refid="bib111" id="crosref0600">111</ce:cross-ref>]. In the tumor microenvironment of patients with chronic lymphocytic leukemia, the expression of PIMs in lymph nodes is significantly higher than in the peripheral blood [<ce:cross-ref refid="bib112" id="crosref0605">112</ce:cross-ref>]. So, PIMs target to redirect the immune system against anti-tumor immunity to protect tumor cells.</ce:para>
                     <ce:para id="p0185" view="all">As PIM kinases exhibited complementary function in oncogenesis and are expressed in different cancers, pan-PIM kinase inhibitors show more promising anti-tumor potency than isoform-selective inhibitors [<ce:cross-ref refid="bib113" id="crosref0610">113</ce:cross-ref>]. Recently, PIMs have been targeted clinically in several cancer studies (<ce:cross-ref refid="tbl4" id="crosref0615">Table 4</ce:cross-ref>
                        <ce:float-anchor refid="tbl3"/></ce:float-anchor>
                        <ce:float-anchor refid="tbl4"/></ce:float-anchor>). <ce:bold>SGI-1776</ce:bold> (SuperGen) is a selective PIM1 inhibitor, entering into Phase I trials in 2009 for the patients with relapsed/refractory leukemias, hormone-refractory prostate cancer and refractory non-Hodgkin's lymphoma. Targeting transcription and translation, <ce:bold>SGI-1776</ce:bold> changes glycosylation and expression of P-glycoprotein on the cell surface [<ce:cross-ref refid="bib114" id="crosref0620">114</ce:cross-ref>]. However, this project has been discontinued because the dose-limiting toxicity of cardiac corrected QT (QTc) prolongation (NCT01239108, NCT00848601). <ce:bold>AZD1208</ce:bold> (AstraZeneca) is a pan-PIM inhibitor in Phase I for the treatment of acute myeloid leukemia, malignant lymphoma and advanced solid tumors, but this development is also terminated for safety and efficacy reasons (NCT01489722, NCT01588548). <ce:bold>PIM-447</ce:bold> (Novartis) is a pan-PIM inhibitor developed for the treatment of multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome and myelofibrosis (NCT02370706) and the Phase II clinical trial is underway. In a disseminated murine model of human myeloma, <ce:bold>PIM-447</ce:bold> blocks the tumor burden and prevents the tumor-associated bone loss [<ce:cross-ref refid="bib115" id="crosref0625">115</ce:cross-ref>]. In heavily pretreated patients with relapsed or refractory multiple myeloma, about 5% of the patients show grade 3/4 adverse events associated with the clinical study. Most adverse events are grade 1/2 and manageable, and no deaths occur during the study. <ce:bold>PIM-447</ce:bold> is well tolerated with a maximum tolerated-dose of 500 mg once daily and exhibits durable single-agent efficacy in multiple patients with a disease control rate of 72% and a best response of VGPR (<ce:cross-ref refid="fig11" id="crosref0630">Fig. 11</ce:cross-ref>
                        <ce:float-anchor refid="fig11"/></ce:float-anchor>) [<ce:cross-ref refid="bib116" id="crosref0635">116</ce:cross-ref>] (see <ce:cross-ref refid="tbl5" id="crosref0640">Table 5</ce:cross-ref>
                        <ce:float-anchor refid="tbl5"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0190" view="all">
                        <ce:bold>PIM-447</ce:bold> is the only PIM kinase inhibitor entering clinical trial of multiple myeloma. And the preliminary clinical results of multiple myeloma are accepted and promising. PIM2 is highly expressed in multiple myeloma and important in regulating survival and development of myeloma cells by blocking apoptosis and inducing cap-dependent translation. Three PIM kinases have complementary and/or overlapped functions in multiple myeloma [<ce:cross-ref refid="bib117" id="crosref0645">117</ce:cross-ref>]. Phase I studies of <ce:bold>PIM447</ce:bold> indicate that disease control rate is 71.9% and most adverse events are grade 1/2 and manageable. Though the clinical trials of <ce:bold>SGI-1776</ce:bold> and <ce:bold>AZD1208</ce:bold> in many hematological malignancies and solid tumors have been terminated for drug safety issues, blocking PIM kinase is still a promising therapeutic approach in patients with multiple myeloma.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.6" view="all">
                     <ce:label>2.6</ce:label>
                     <ce:section-title id="sectitle0065">IRAK4</ce:section-title>
                     <ce:para id="p0195" view="all">IRAK4, interleukin-1 receptor associated kinase 4, is a serine/threonine kinase and a key intersection point of Toll-like receptors (TLRs) and interleukin-1 (IL-1) family receptors in the innate inflammatory signaling [<ce:cross-ref refid="bib118" id="crosref0650">118</ce:cross-ref>]. IRAK4 is expressed in T and B lymphocytes and regulates the expression of proinflammatory cytokines and Type I IFNs through Myd88-dependent signaling [<ce:cross-refs refid="bib119 bib120 bib121" id="crosrefs0055">119–121</ce:cross-refs>]. IRAK4 is activated by binding with death domain of MyD88 and can lead to the phosphorylation of IRAK1 and/or IRAK2. Subsequent signaling leads to the activation of NF-κB and the expression of various chemoattractants resulting in disease pathology (<ce:cross-ref refid="fig12" id="crosref0655">Fig. 12</ce:cross-ref>
                        <ce:float-anchor refid="fig12"/></ce:float-anchor>) [<ce:cross-refs refid="bib122 bib123 bib124" id="crosrefs0060">122–124</ce:cross-refs>].</ce:para>
                     <ce:para id="p0200" view="all">IRAK4 is identified as a target for therapeutic intervention based on the study of a small part of individuals deficient in IRAK4 [<ce:cross-ref refid="bib125" id="crosref0660">125</ce:cross-ref>]. Blood samples of IRAK4-deficient patients show a weaker response to Toll-like receptor signal and MAPK-stimulated cytokines are not observed exposed to LPS. IRAK4-deficient people exhibited damaged activation of the innate immune system, but there is no more susceptibility to recurrent pneumococcal and staphylococcal infections [<ce:cross-ref refid="bib126" id="crosref0665">126</ce:cross-ref>]. IRAK4-dependent Toll-like receptors are essential to childhood immunity. But, because that adaptive immunity can compensate for the weak innate immunity in the patients, IRAK4-dependent Toll-like receptors are not indispensable to the protective immunity [<ce:cross-ref refid="bib127" id="crosref0670">127</ce:cross-ref>]. IRAK4-KD mice exhibit decreasing activation of IL-1-induced NF-κB compared to WT mice, which validates the function of IRAK4 signaling pathway [<ce:cross-ref refid="bib121" id="crosref0675">121</ce:cross-ref>,<ce:cross-ref refid="bib128" id="crosref0680">128</ce:cross-ref>]. Furthermore, IRAK4-deficient mice are resistant to lethal dosage of LPS [<ce:cross-ref refid="bib129" id="crosref0685">129</ce:cross-ref>]. As IRAK4 inhibitors reduce the production of IL-1, TNF-α and other proinflammatory cytokines, targeting this signaling pathway could have great therapeutic benefit for autoimmune/inflammatory diseases and oncology.</ce:para>
                     <ce:para id="p0205" view="all">Toll-like receptors and IL-1 family ligands activate NF-κB through IRAK4 signaling pathway and stimulate the production of cytokine and chemokine that promote the development and survival of tumor cell [<ce:cross-ref refid="bib119" id="crosref0690">119</ce:cross-ref>]. Immunohistological studies have reported that p-IRAK4 is expressed highly in various tumor tissues [<ce:cross-ref refid="bib130" id="crosref0695">130</ce:cross-ref>]. And IRAK4 inhibitors have been studied to treat multiple cancers including melanoma, T-acute lymphoblastic leukemia and activated B cell diffuse large B-cell lymphoma (ABC-DLBCL) [<ce:cross-ref refid="bib131" id="crosref0700">131</ce:cross-ref>]. IRAK4 inhibitor alleviates the LPS-induced TNF expression, collagen-induced arthritis and gout formation in mouse models. And IRAK4 inhibitors reduce the growth and metastasis of ABC-DLBCL xenograft models both individually and in combination with other therapies [<ce:cross-ref refid="bib132" id="crosref0705">132</ce:cross-ref>,<ce:cross-ref refid="bib133" id="crosref0710">133</ce:cross-ref>], indicating that IRAK4 inhibition can gain a therapeutic profit for certain cancer indications.</ce:para>
                     <ce:para id="p0210" view="all">In recent years, many companies make great efforts to identify safe, potent and selective IRAK4 inhibitors suitable for clinical study. Nowadays, there are three selective IRAK4 inhibitors in clinical trials: <ce:bold>PF-06650833</ce:bold> (Pfizer) has been approved for the treatment of rheumatoid arthritis in Phase II clinical trials; <ce:bold>BAY 1834845</ce:bold> (Bayer, structure undisclosed) is in Phase I trials for the treatment of pelvic inflammatory disease and endometriosis; <ce:bold>CA-4948</ce:bold> (Curis and Aurigene, structure undisclosed) was approved for Phase I clinical trials of relapsed or refractory non-Hodgkin lymphoma in November 2017. In patient-derived xenograft models of ABC-DLBCL, <ce:bold>CA-4948</ce:bold> showed great anti-tumor activity. And combination of <ce:bold>CA-4948</ce:bold> and Bcl-2 inhibitor <ce:bold>Venetoclax</ce:bold> exhibited much greater anti-tumor response compared to the single administration. The group at AstraZeneca has identified <ce:bold>Compound A</ce:bold>, which can block the activation NF-κB and the growth of ABC-DLBCL cell <ce:italic>in vitro</ce:italic>. In combination with <ce:bold>Ibrutinib</ce:bold>, this compound can suppress growth and development of ABC-DLBCL <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> significantly [<ce:cross-ref refid="bib134" id="crosref0715">134</ce:cross-ref>]. <ce:bold>Compound B</ce:bold>, reported by Bayer, can inhibit the production of IL-6 and IL-8 in human TMD-8 DLBCL cell line with an IC<ce:inf loc="post">50</ce:inf> between 1 and 10 μM and induce a robust dose-dependent reduction of TNF-α production at 10, 40 and 80 mg/kg. Some patents, disclosed by Nimbus Therapeutics, describe a large number of IRAK4 inhibitor for autoimmune disorders and oncology. <ce:bold>ND-2110</ce:bold> and <ce:bold>ND-2158</ce:bold> suppressed the expression of the proinflammatory cytokine TNF in human white blood cells stimulated by TLR4 agonist LPS or TLR9 agonist CpG. <ce:bold>ND-2158</ce:bold> and its combination with BTK inhibitor or Bcl-2 inhibitor can block tumor growth in ABC-DLBCL xenograft models significantly [<ce:cross-ref refid="bib132" id="crosref0720">132</ce:cross-ref>]. Currently, Nimbus cooperating with Genetech is moving an undisclosed IRAK4 inhibitor into clinical trials (<ce:cross-ref refid="fig13" id="crosref0725">Fig. 13</ce:cross-ref>
                        <ce:float-anchor refid="fig13"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0215" view="all">Many companies and institutions are forming strategic partnerships to accelerate the preclinical development and bring more IRAK4 inhibitor forward to clinical trials for the treatment of oncological indications, including Nimbus/Genetech, TG Therapeutics/Ligand and Aurigene/Curius. And, these inhibitors will lead to a new treatment option for millions of cancer patients.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.7" view="all">
                     <ce:label>2.7</ce:label>
                     <ce:section-title id="sectitle0070">RON/MST1R</ce:section-title>
                     <ce:para id="p0220" view="all">RON (also known as macrophage stimulating 1 receptor, MST1R) is a c-Met related tyrosine kinase, mainly expressed by epithelial cells, osteoclasts and macrophages. Macrophage stimulating 1 (also known as macrophage-stimulating protein, MSP) is a glycoprotein released from the liver into the blood as an inactive precursor, and MSP is cleaved and activated locally on macrophages by the macrophage protease-suppression of tumorigenicity 14 (ST14/matriptase) [<ce:cross-ref refid="bib135" id="crosref0730">135</ce:cross-ref>]. Activated MSP can bind with the receptor RON to regulate the cell proliferation, survival and chemotaxis.</ce:para>
                     <ce:para id="p0225" view="all">Though MSP or RON deficient mice show no obvious physiological defect, they are susceptible to the toxic shock after infection or injury because the disability of their macrophages to downregulate pro-inflammatory cytokines [<ce:cross-ref refid="bib136" id="crosref0735">136</ce:cross-ref>,<ce:cross-ref refid="bib137" id="crosref0740">137</ce:cross-ref>]. RON also has been reported to play a pivotal role in various cancers. ST14 and RON are highly expressed in about 45% and 50% of human breast carcinomas respectively, and the overexpression of MSP, ST14 and RON indicate the poor prognosis of metastasis and death among breast carcinoma patients [<ce:cross-ref refid="bib138" id="crosref0745">138</ce:cross-ref>]. In addition of being involved in tumorigenesis directly, RON can favor the polarization of tumor-associated macrophages to the immunosuppressive M2-like phenotype [<ce:cross-ref refid="bib139" id="crosref0750">139</ce:cross-ref>]. In RON<ce:sup loc="post">−/-</ce:sup> mice, Arg1 expression of tumor-associated macrophages is significantly reduced compared with that in WT, and reduced Arg1 production leads to weaker syngeneic tumor growth in these animals [<ce:cross-ref refid="bib140" id="crosref0755">140</ce:cross-ref>]. Expressing higher levels of TNF-α and IL-12 in the same mice model, CD8<ce:sup loc="post">+</ce:sup> T cells show more robust cytolytic activity <ce:italic>in vitro</ce:italic> than WT. And the enhanced antitumor response of CD8<ce:sup loc="post">+</ce:sup> T cell blocks the pulmonary metastasis of micrometastatic cancer cells [<ce:cross-ref refid="bib141" id="crosref0760">141</ce:cross-ref>].</ce:para>
                     <ce:para id="p0230" view="all">
                        <ce:bold>BMS-777607</ce:bold> (Bristol-Myers Squibb) is a selective inhibitor of RON in Phase I clinical trials for the treatment of advanced or metastatic solid tumors. Importantly, the anti-metastatic activity of <ce:bold>BMS-777607</ce:bold> relies on CD8<ce:sup loc="post">+</ce:sup> T cells, because this efficacy is fully lost in the context of CD8<ce:sup loc="post">+</ce:sup> T cell depletion [<ce:cross-ref refid="bib141" id="crosref0765">141</ce:cross-ref>]. <ce:bold>MK-8033</ce:bold> (Merk) is the dual inhibitor of RON and MET and the Phase I clinical trial of this inhibitor for advanced solid tumors has been completed in 2008. Clinical data of <ce:bold>BMS-777607</ce:bold> and <ce:bold>MK-8033</ce:bold> reveal that both of them are well-tolerated and most of adverse events are manageable. But, clinical efficacy of <ce:bold>MK-8033</ce:bold> is limited: only one patient achieves a partial response and eight patients achieve a best response of stable disease. Based on limited clinical efficacy, the clinical development of <ce:bold>MK-8033</ce:bold> is discontinued unfortunately. At the same time, the clinical studies of <ce:bold>BMS-777607</ce:bold> have not progressed for many years.</ce:para>
                     <ce:para id="p0235" view="all">Considering that both of <ce:bold>BMS-777607</ce:bold> and <ce:bold>MK-8033</ce:bold> seem to reach an impasse, the clinical success of RON inhibitors may require a well design of clinical trials, the selection of specific patients and the development/exploitation of immunological biomarkers (<ce:cross-ref refid="fig14" id="crosref0770">Fig. 14</ce:cross-ref>
                        <ce:float-anchor refid="fig14"/></ce:float-anchor>).</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0075">Conclusion and future perspectives</ce:section-title>
                  <ce:para id="p0240" view="all">As inflammatory diseases promote the development of tumors, cancer and abnormalities inflammation appear to go hand in hand. Immunity and inflammation are central points in the initiation, development, elimination or prolongation of cancer transformation by providing growth factors and cytokines. In this review, we have highlighted kinase signal transduction pathways and the relevant targets that have the potential to reverse the immunosuppressive tumor microenvironment and induce a stronger immune response to cancer.</ce:para>
                  <ce:para id="p0245" view="all">In the recent few years, tremendous advances in the development of immunotherapy for the cancer patients have been achieved. Of them, it is the large molecules targeting CTLA-4, PD-l/PD-L1 and VISTA that lead the way in particular. Developing novel small-molecule modulators against intracellular targets for improved efficacy remains highly desirable. In addition, with the advantages of lower costs of goods and favorable pharmacokinetics, small-molecule modulators provide an alternative for patients who failed in large-molecule therapies or who would benefit from combination therapies. Kinases have been researched as drug targets in cancer therapies for over 30 years. Considering that kinases are suitable to be targeted by small-molecule inhibitors, developing immunity protein kinase inhibitors deserves more research and investment and there are reasons to be cautiously optimistic that these inhibitors can become a significant therapy in immuno-oncology. Our laboratory has studied immunity protein kinase (MNKs and IRAK4) inhibitors for a few years. Now we have obtained highly active and selective compounds and we are cooperating with pharmaceutical company for further development.</ce:para>
                  <ce:para id="p0250" view="all">Last but not least, though the therapy of orally and available small-molecule protein kinase inhibitor seems realistic in immuno-oncology, many clinical results demonstrate that these kinase inhibitors are not sufficient to eliminate tumor as a monotherapy. And increasing evidences exist to support the synergy among different kinds of immunotherapeutic agents or the combinational immunotherapy with chemotherapy, irradiation or target therapies.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0080">Acknowledgements</ce:section-title>
               <ce:para id="p0255" view="all">This research was supported by the <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100004608" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Natural Science Foundation of Jiangsu Province</ce:grant-sponsor> (No.<ce:grant-number refid="gs1">BK20141349</ce:grant-number>) and the <ce:grant-sponsor id="gs2" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">China National Key Hi-Tech Innovation Project for the R&D of Novel Drugs</ce:grant-sponsor> (No.<ce:grant-number refid="gs2">2013ZX09301303-002</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0085">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Bryan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Rajapaksa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase inhibitors for the treatment of immunological disorders: recent advances</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9030</sb:first-page>
                              <sb:last-page>9058</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1021/acs.jmedchem.8b00667" id="intref0010" xlink:type="simple">https://doi: 10.1021/acs.jmedchem.8b00667</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Nathan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Points of control in inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>420</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>846</sb:first-page>
                              <sb:last-page>852</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1038/nature01320" id="intref0015" xlink:type="simple">https://doi.org/10.1038/nature01320</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dreas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mikulski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Milik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Fabritius</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Brzózka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Rzymski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: recent progress in the development of MNK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3025</sb:first-page>
                              <sb:last-page>3053</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.2174/0929867324666170203123427" id="intref0020" xlink:type="simple">https://doi: 10.2174/0929867324666170203123427</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Schmid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Avraamides</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.C.</ce:given-name>
                                 <ce:surname>Dippold</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Franco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Foubert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.G.</ce:given-name>
                                 <ce:surname>Ellies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Acevedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.E.</ce:given-name>
                                 <ce:surname>Manglicmot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wrasidlo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3K gamma, a single convergent point promoting tumor inflammation and progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>715</sb:first-page>
                              <sb:last-page>727</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/j.ccr.2011.04.016" id="intref0025" xlink:type="simple">https://doi.org/10.1016/j.ccr.2011.04.016</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gaestel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kotlyarov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kracht</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting innate immunity protein kinase signalling in inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>480</sb:first-page>
                              <sb:last-page>499</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1038/nrd2829" id="intref0030" xlink:type="simple">https://doi.org/10.1038/nrd2829</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Pfister</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Warne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Doyle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Aikawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Amiri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Appleton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of a selective and potent inhibitor of mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1/2) utilizing structure-based drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3034</sb:first-page>
                              <sb:last-page>3045</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1021/acs.jmedchem.5b01657" id="intref0035" xlink:type="simple">https://doi: 10.1021/acs.jmedchem.5b01657</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Webster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.K.</ce:given-name>
                                 <ce:surname>Goel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Staunton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.N.</ce:given-name>
                                 <ce:surname>Hung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Parker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Stumpf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Molter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.G.</ce:given-name>
                                 <ce:surname>Chiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Wegerski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sperry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Thompson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Ernst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Webber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Sprengeler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Reich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>eFT508: an oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>PR11</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.G.</ce:given-name>
                                 <ce:surname>Wendel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Silva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Malina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Mills</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ueda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Watanabefukunaga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fukunaga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Teruyafeldstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pelletier</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dissecting eIF4E action in tumorigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Gene Dev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3232</sb:first-page>
                              <sb:last-page>32237</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1101/gad.1604407" id="intref0040" xlink:type="simple">https://doi: 10.1101/gad.1604407</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sonali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.P.</ce:given-name>
                                 <ce:surname>Leonidas</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mnk kinases in cytokine signaling and regulation of cytokine responses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biomol. Concepts</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>127</sb:first-page>
                              <sb:last-page>139</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1515/bmc-2011-2000" id="intref0045" xlink:type="simple">https://doi: 10.1515/bmc-2011-2000</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>De</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>eIF4E expression in tumors: its possible role in progression of malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Biochem. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>59</sb:first-page>
                              <sb:last-page>72</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/S1357-2725(98)00132-0" id="intref0050" xlink:type="simple">https://doi.org/10.1016/S1357-2725(98)00132-0</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.E.</ce:given-name>
                                 <ce:surname>Kleiner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Krishnan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tubbs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Meschonat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lowery-Nordberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Adegboyega</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Unger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cardelli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5</sb:first-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1186/1756-9966-28-5" id="intref0055" xlink:type="simple">https://doi.org/10.1186/1756-9966-28-5</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Dasilva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.T.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Barsagi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of sprouty stability by Mnk1-dependent phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1898</sb:first-page>
                              <sb:last-page>1907</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1128/MCB.26.5.1898-1907.2006" id="intref0060" xlink:type="simple">https://doi: 10.1128/MCB.26.5.1898-1907.2006</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Buxadé</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Parra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rousseau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shpiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Marquez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Morrice</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Espel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Proud</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Mnks are novel components in the control of TNFα biosynthesis and phosphorylate and regulate hnRNP A1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunity</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>177</sb:first-page>
                              <sb:last-page>189</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/j.immuni.2005.06.009" id="intref0065" xlink:type="simple">https://doi.org/10.1016/j.immuni.2005.06.009</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Buxadé</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Morrice</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Krebs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Proud</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The PSF.p54(nrb) complex is a novel Mnk substrate that binds the mRNA for tumor necrosis factor alpha</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>283</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>57</sb:first-page>
                              <sb:last-page>65</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1074/jbc.M705286200" id="intref0070" xlink:type="simple">https://doi: 10.1074/jbc.M705286200</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hefner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Borsch-Haubold</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Murakami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Wilde</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pasquet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Schieltz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ghomashchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Yates</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Armstrong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Paterson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fukunaga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hunter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Kudo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Watson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Gelb</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>275</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>37542</sb:first-page>
                              <sb:last-page>37551</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1074/jbc.M003395200" id="intref0075" xlink:type="simple">https://doi: 10.1074/jbc.M003395200</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ueda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Watanabefukunaga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Fukuyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nagata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fukunaga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6539</sb:first-page>
                              <sb:last-page>6549</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1128/MCB.24.15.6539-6549.2004" id="intref0080" xlink:type="simple">https://doi: 10.1128/MCB.24.15.6539-6549.2004</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Joshi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Platanias</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mnk kinase pathway: cellular functions and biological outcomes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>World J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>321</sb:first-page>
                              <sb:last-page>333</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.4331/wjbc.v5.i3.321" id="intref0085" xlink:type="simple">https://doi: 10.4331/wjbc.v5.i3.321</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ueda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sasaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Elia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.I.</ce:given-name>
                                 <ce:surname>Chio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hamada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fukunaga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Mak</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>13984</sb:first-page>
                              <sb:last-page>13990</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1073/pnas.1008136107" id="intref0090" xlink:type="simple">https://doi: 10.1073/pnas.1008136107</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Knauf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tschopp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Gram</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5500</sb:first-page>
                              <sb:last-page>5511</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1128/MCB.21.16.5500-5511.2001" id="intref0095" xlink:type="simple">https://doi: 10.1128/MCB.21.16.5500-5511.2001</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Wheater</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Blaydes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Biol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>728</sb:first-page>
                              <sb:last-page>735</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.4161/cbt.10.7.12965" id="intref0100" xlink:type="simple">https://doi: 10.4161/cbt.10.7.12965</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Evans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Geradts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Bao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jolly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Vermeulen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Palmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gromeier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Levine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Morse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Van Laere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Devi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>XIAP regulation by MNK links MAPK and NFκB signaling to determine an aggressive breast cancer phenotype</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>78</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1726</sb:first-page>
                              <sb:last-page>1738</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1158/0008-5472.CAN-17-1667" id="intref0105" xlink:type="simple">https://doi: 10.1158/0008-5472.CAN-17-1667</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Schenone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Musumec</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Brullo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Botta</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biologically driven synthesis of pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors: an old scaffold as a new tool for medicinal chemistry and chemical biology studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>114</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7189</sb:first-page>
                              <sb:last-page>7238</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1021/cr400270z" id="interref0010" xlink:type="simple">https://doi: 10.1021/cr400270z</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zuccotto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ardini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Casale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Angiolini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Through the "gatekeeper door": exploiting the active kinase conformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2681</sb:first-page>
                              <sb:last-page>2694</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1021/jm901443h" id="intref0115" xlink:type="simple">https://doi: 10.1021/jm901443h</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <ce:other-ref id="sref24">
                        <ce:textref>K. Eis, F. Puehler, L. Zorn, A. Scholz, P. Lienau, M.J. Gnoth, U. Bömer, J. Günther, M. Hitchcock, Amino-substituted Imidazopyridazines, WO2013144189.</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <ce:other-ref id="sref25">
                        <ce:textref>E. Knu, Amino- Substituted Imidazopyridazines, WO2013087581.</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Santag</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Siegel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Wengner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lange</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Bömer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Eis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Pühler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Lienau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bergemann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Michels</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>390</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>21</sb:first-page>
                              <sb:last-page>29</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1016/j.canlet.2016.12.029" id="intref0120" xlink:type="simple">https://doi: 10.1016/j.canlet.2016.12.029</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Santag</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Siegel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Wegner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schneider</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Boemer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Eis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Puehler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Michels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.V.</ce:given-name>
                                 <ce:surname>Nussbaum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ziegelbauer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preclinical anti-tumor efficacy and mode of action of a novel, orally available, selective MKNK1 inhibitor [BAY 1143269]</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>75</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2604</sb:first-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1158/1538-7445" id="intref0125" xlink:type="simple">https://doi: 10.1158/1538-7445</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Webster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.K.</ce:given-name>
                                 <ce:surname>Goel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.N.</ce:given-name>
                                 <ce:surname>Hung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Parker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Staunton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Neal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Molter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.G.</ce:given-name>
                                 <ce:surname>Chiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Jessen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Wegerski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sperry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Thompson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Appleman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Webber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Sprengeler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Reich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>eFT508, a potent and selective mitogen-activated protein kinase interacting kinase (MNK) 1 and 2 inhibitor, is efficacious in preclinical models of diffuse large B-cell lymphoma (DLBCL)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>126</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1554</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Gopal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ramchandren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.Y.</ce:given-name>
                                 <ce:surname>Gabrail</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Goel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.G.</ce:given-name>
                                 <ce:surname>Chiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Webster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sperry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.T.</ce:given-name>
                                 <ce:surname>Vallner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Casseday</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Barton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A phase 1-2 dose-escalation and cohort- expansion study of eFT508, a selective, orally bioavailable inhibitor of MNK1 and MNK2, in patients with hematological malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>130</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4624</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Chennamaneni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Ang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Jeyaraj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Yeap</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.H.</ce:given-name>
                                 <ce:surname>Ong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Joy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Optimization of selective mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2) inhibitors for the treatment of blast crisis leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4348</sb:first-page>
                              <sb:last-page>4369</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1021/acs.jmedchem.7b01714" id="intref0130" xlink:type="simple">https://doi: 10.1021/acs.jmedchem.7b01714</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Teneggi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Novotny-Diermayr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yasin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yeo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ethirajulu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Blanchard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nellore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Umrani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kassoum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Matter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>First-in-human Phase I study of ETC-206 an oral MNK1/2 kinase inhibitor in healthy volunteers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>103</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S89</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Timothy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Daniela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.W.</ce:given-name>
                                 <ce:surname>Douglas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8559</sb:first-page>
                              <sb:last-page>8581</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1021/jm300847w" id="intref0135" xlink:type="simple">https://doi: 10.1021/jm300847w</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.T.</ce:given-name>
                                 <ce:surname>Houseman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Kunkel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Aizenstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.A.</ce:given-name>
                                 <ce:surname>Knight</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Shokat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of dual inhibitors of the immune cell PI3Ks p110δ and p110γ: a prototype for new anti-inflammatory drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>123</sb:first-page>
                              <sb:last-page>134</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/j.chembiol.2010.01.010" id="intref0140" xlink:type="simple">https://doi.org/10.1016/j.chembiol.2010.01.010</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vanhaesebroeck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guillermetguibert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Graupera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Bilanges</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The emerging mechanisms of isoform-specific PI3K signalling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>329</sb:first-page>
                              <sb:last-page>341</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1038/nrm2882" id="intref0145" xlink:type="simple">https://doi: 10.1038/nrm2882</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Okkenhaug</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Graupera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vanhaesebroeck</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1090</sb:first-page>
                              <sb:last-page>1105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1158/2159-8290.CD-16-0716" id="intref0150" xlink:type="simple">https://doi: 10.1158/2159-8290.CD-16-0716</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Soond</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Piñeiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hagemann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Pearce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.L.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Bouabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Scudamore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hancox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Maecker</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>510</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>407</sb:first-page>
                              <sb:last-page>411</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1038/nature13444" id="intref0155" xlink:type="simple">https://doi: 10.1038/nature13444</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Roychoudhuri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Eil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.P.</ce:given-name>
                                 <ce:surname>Restifo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The interplay of effector and regulatory T cells in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>101</sb:first-page>
                              <sb:last-page>111</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1016/j.coi.2015.02.003" id="intref0160" xlink:type="simple">https://doi: 10.1016/j.coi.2015.02.003</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kishore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Gittens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Coe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Komarowska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Infante</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Ridley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cooper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Perretti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Self-recognition of the endothelium enables regulatory T-cell trafficking and defines the kinetics of immune regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3436</sb:first-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1038/ncomms4436" id="intref0165" xlink:type="simple">https://doi: 10.1038/ncomms4436</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Foubert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kaneda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Varner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PI3Kgamma activates integrin alpha4 and promotes immune suppressive myeloid cell polarization during tumor progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer. Immunol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>957</sb:first-page>
                              <sb:last-page>968</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1158/2326-6066.CIR-17-0143" id="intref0170" xlink:type="simple">https://doi: 10.1158/2326-6066.CIR-17-0143</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Kaneda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Messer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ralainirina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Leem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gorjestani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Woo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Nguyen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Figueiredo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Foubert</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PI3Kγ is a molecular switch that controls immune suppression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>539</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>437</sb:first-page>
                              <sb:last-page>442</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1038/nature19834" id="intref0175" xlink:type="simple">https://doi: 10.1038/nature19834</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Byrd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Coutre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Benson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.W.</ce:given-name>
                                 <ce:surname>Flinn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.D.</ce:given-name>
                                 <ce:surname>Wagnerjohnston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Spurgeon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Kahl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Bello</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.K.</ce:given-name>
                                 <ce:surname>Webb</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>123</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3390</sb:first-page>
                              <sb:last-page>3397</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1182/blood-2013-11-535047" id="intref0180" xlink:type="simple">https://doi: 10.1182/blood-2013-11-535047</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Hall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Katiyar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Rumberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Leffet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>INCB040093 is a novel PI3Kδ inhibitor for the treatment of B cell lymphoid malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharmacol. Exp. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>364</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>120</sb:first-page>
                              <sb:last-page>130</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1124/jpet.117.244947" id="intref0185" xlink:type="simple">https://doi: 10.1124/jpet.117.244947</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Evans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lescarbeau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Nair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Grenier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Pradeilles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Glenadel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tibbitts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Rowley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Dinitto</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of a selective Phosphoinositide-3-Kinase(PI3K)-γ inhibitor (IPI-549) as an immuno-oncology clinical candidate</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>862</sb:first-page>
                              <sb:last-page>867</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1021/acsmedchemlett.6b00238" id="intref0190" xlink:type="simple">https://doi: 10.1021/acsmedchemlett.6b00238</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.D.</ce:given-name>
                                 <ce:surname>Henau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Merghoub</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Winkler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tchaicha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rausch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Proctor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kosmider</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Soglia</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Abstract 554: checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>76</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S554</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.D.</ce:given-name>
                                 <ce:surname>Henau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rausch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Winkler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.F.</ce:given-name>
                                 <ce:surname>Campesato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Cymerman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Budhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ghosh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tchaicha</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>539</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>443</sb:first-page>
                              <sb:last-page>447</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1038/nature20554" id="intref0195" xlink:type="simple">https://doi: 10.1038/nature20554</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Reif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Okkenhaug</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sasaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Penninger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vanhaesebroeck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Cyster</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>173</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2236</sb:first-page>
                              <sb:last-page>2240</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.4049/jimmunol.173.4.2236" id="intref0200" xlink:type="simple">https://doi.org/10.4049/jimmunol.173.4.2236</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.W.</ce:given-name>
                                 <ce:surname>Flinn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>O'Brien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kahl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Oki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.F.</ce:given-name>
                                 <ce:surname>Foss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Porcu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Burger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Jain</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>877</sb:first-page>
                              <sb:last-page>887</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1182/blood-2017-05-786566" id="intref0205" xlink:type="simple">https://doi: 10.1182/blood-2017-05-786566</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Horwitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Koch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Porcu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Oki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Moskowitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Perez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Myskowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Officer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Jaffe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Morrow</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>131</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>888</sb:first-page>
                              <sb:last-page>898</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1182/blood-2017-08-802470" id="intref0210" xlink:type="simple">https://doi: 10.1182/blood-2017-08-802470</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Winkler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Faia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Dinitto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>White</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.E.</ce:given-name>
                                 <ce:surname>Brophy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Pink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Proctor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lussier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1364</sb:first-page>
                              <sb:last-page>1374</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1016/j.chembiol.2013.09.017" id="intref0215" xlink:type="simple">https://doi: 10.1016/j.chembiol.2013.09.017</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Coutré</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Barrientos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Vos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Furman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Keating</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>O'Brien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Pagel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Poleski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Management of adverse events associated with idelalisib treatment: expert panel opinion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Lymphoma</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2779</sb:first-page>
                              <sb:last-page>2786</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.3109/10428194.2015.1022770" id="intref0220" xlink:type="simple">https://doi: 10.3109/10428194.2015.1022770</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hirsch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.L.</ce:given-name>
                                 <ce:surname>Katanaev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Garlanda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Azzolino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Pirola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Silengo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sozzani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mantovani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Altruda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Wymann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>287</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1049</sb:first-page>
                              <sb:last-page>1053</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1126/science.287.5455.1049" id="intref0225" xlink:type="simple">https://doi: 10.1126/science.287.5455.1049</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Siragusa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Katare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Meloni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Damilano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hirsch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Emanueli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Madeddu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Circ. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>106</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>757</sb:first-page>
                              <sb:last-page>768</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1161/CIRCRESAHA.109.207449" id="intref0230" xlink:type="simple">https://doi: 10.1161/CIRCRESAHA.109.207449</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Strobl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Stoiber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sexl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mueller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Biosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3214</sb:first-page>
                              <sb:last-page>3232</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.2741/3908" id="intref0235" xlink:type="simple">https://doi.org/10.2741/3908</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ghoreschi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laurence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>O'Shea</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Janus kinases in immune cell signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunol. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>228</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>273</sb:first-page>
                              <sb:last-page>287</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1111/j.1600-065X.2008.00754.x" id="intref0240" xlink:type="simple">https://doi.org/10.1111/j.1600-065X.2008.00754.x</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Velazquez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fellous</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Stark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pellegrini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A protein tyrosine kinase in the interferon αβ signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>70</sb:volume-nr>
                              </sb:series>
                              <sb:date>1992</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>313</sb:first-page>
                              <sb:last-page>322</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/0092-8674(92)90105-L" id="intref0245" xlink:type="simple">https://doi.org/10.1016/0092-8674(92)90105-L</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.R.</ce:given-name>
                                 <ce:surname>Leitner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Witalisz-Siepracka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Strobl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Müller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase 2 - surveillant of tumours and bona fide oncogene</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytokine</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>89</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>209</sb:first-page>
                              <sb:last-page>218</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1016/j.cyto.2015.10.015" id="intref0250" xlink:type="simple">https://doi: 10.1016/j.cyto.2015.10.015</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Neubauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cumano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mã¼Ller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Huffstadt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Pfeffer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>93</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>397</sb:first-page>
                              <sb:last-page>409</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/S0092-8674(00)81168-X" id="intref0255" xlink:type="simple">https://doi.org/10.1016/S0092-8674(00)81168-X</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Rodig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Meraz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>White</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Lampe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Riley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Arthur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>King</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Sheehan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pennica</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>93</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>373</sb:first-page>
                              <sb:last-page>383</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/S0092-8674(00)81166-6" id="intref0260" xlink:type="simple">https://doi.org/10.1016/S0092-8674(00)81166-6</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nosaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Van</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Tripp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.E.</ce:given-name>
                                 <ce:surname>Thierfelder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Witthuhn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Mcmickle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>Doherty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.C.</ce:given-name>
                                 <ce:surname>Grosveld</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>Ihle</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Defective lymphoid development in mice lacking Jak3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>270</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>800</sb:first-page>
                              <sb:last-page>802</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1126/science.270.5237.800" id="intref0265" xlink:type="simple">https://doi: 10.1126/science.270.5237.800</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Saijo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Osawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Arase</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Hirayama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Miyake</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nakauchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Shirasawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Saito</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Developmental defects of lymphoid cells in Jak3 kinase-deficient mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunity</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>771</sb:first-page>
                              <sb:last-page>782</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/1074-7613(95)90066-7" id="intref0270" xlink:type="simple">https://doi.org/10.1016/1074-7613(95)90066-7</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Tao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.F.</ce:given-name>
                                 <ce:surname>Zou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.M.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.Q.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Biol. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4663</sb:first-page>
                              <sb:last-page>4672</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1007/s11033-010-0601-5" id="intref0275" xlink:type="simple">https://doi: 10.1007/s11033-010-0601-5</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.D.S.</ce:given-name>
                                 <ce:surname>Cunninghame</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Morris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.R.</ce:given-name>
                                 <ce:surname>Bhangale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Criswell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ann-Christine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lars</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Behrens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Vyse</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>e1002341</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1371/journal.pgen.1002341" id="intref0280" xlink:type="simple">https://doi: 10.1371/journal.pgen.1002341</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ban</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Lorentzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Baker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mihalova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ingram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Booth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.N.</ce:given-name>
                                 <ce:surname>Heard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Stewart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Bogaert</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Hum. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1309</sb:first-page>
                              <sb:last-page>1313</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1038/ejhg.2009.41" id="intref0285" xlink:type="simple">https://doi: 10.1038/ejhg.2009.41</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Diogo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bastarache</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.P.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Fulton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Greenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Eyre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bowes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PloS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>e0122271</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1371/journal.pone.0122271" id="intref0290" xlink:type="simple">https://doi: 10.1371/journal.pone.0122271</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Marroqui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Dos Santos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Flã,Yel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.A.</ce:given-name>
                                 <ce:surname>Grieco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Santin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>d.B.A.</ce:given-name>
                                 <ce:surname>Op</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Marselli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Marchetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Pociot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Eizirik</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TYK2, a candidate gene for type 1 diabetes, modulates apoptosis and the innate immune response in human pancreatic β-Cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Diabetes</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>64</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3808</sb:first-page>
                              <sb:last-page>3817</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:comment>https://doi: 10.2337/db15-0362</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ide</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakagawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Terado</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kamiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Muto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Horie</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Biophys. Res. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>369</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>292</sb:first-page>
                              <sb:last-page>296</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/j.bbrc.2007.08.160" id="intref0295" xlink:type="simple">https://doi.org/10.1016/j.bbrc.2007.08.160</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ubel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mousset</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Trufa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sirbu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Finotto</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Establishing the role of tyrosine kinase 2 in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>OncoImmunology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>e22840</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.4161/onci.22840" id="intref0300" xlink:type="simple">https://doi.org/10.4161/onci.22840</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Stoiber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kovacic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schuster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schellack</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Karaghiosoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kreibich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Weisz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Artwohl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.C.</ce:given-name>
                                 <ce:surname>Kleine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Muller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TYK2 is a key regulator of the surveillance of B lymphoid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>114</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1650</sb:first-page>
                              <sb:last-page>1658</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>[69]</ce:label>
                     <sb:reference id="sref69">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Michaela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Agnieszka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.T.</ce:given-name>
                                 <ce:surname>Bednarik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.E.</ce:given-name>
                                 <ce:surname>Maria</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Dagmar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Katrin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Veronika</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mathias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Birgit</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>OncoImmunology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>e1047579</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1080/2162402X.2015.1047579" id="intref0305" xlink:type="simple">https://doi.org/10.1080/2162402X.2015.1047579</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>[70]</ce:label>
                     <sb:reference id="sref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Akahane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Etchin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Berezovskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gjini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Masse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Miao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rocnik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kapeller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Greenwood</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Haematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>177</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>271</sb:first-page>
                              <sb:last-page>282</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1111/bjh.14563" id="intref0310" xlink:type="simple">https://doi: 10.1111/bjh.14563</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>[71]</ce:label>
                     <sb:reference id="sref71">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Masse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Miao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Greenwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kapeller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Westlin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent and Selective Tyk2 Inhibitors Block Th1- and Th17- Mediated Immune Responses and Reduce Disease Progression in Rodent Models of Delayed-type Hypersensitivity and Psoriasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2015</sb:date>
                              <sb:publisher>
                                 <sb:name>ACR</sb:name>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>[72]</ce:label>
                     <sb:reference id="sref72">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Reader</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Characterisation of TYK2 inhibitors as potential T-cell acute lymphoblastic leukaemia therapeutics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S22</sb:first-page>
                              <sb:last-page>S23</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/S0959-8049(16)32648-X" id="intref0315" xlink:type="simple">https://doi.org/10.1016/S0959-8049(16)32648-X</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib73">
                     <ce:label>[73]</ce:label>
                     <sb:reference id="sref73">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Krishnaiah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sreenu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.B.</ce:given-name>
                                 <ce:surname>Subrahmanyam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Sheen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4213</sb:first-page>
                              <sb:last-page>4238</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1021/jm500115w" id="intref0320" xlink:type="simple">https://doi: 10.1021/jm500115w</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib74">
                     <ce:label>[74]</ce:label>
                     <sb:reference id="sref74">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Walker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Dearing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Gallacher</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Relationship of transforming growth factor β1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:date>1994</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1160</sb:first-page>
                              <sb:last-page>1165</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1038/bjc.1994.228" id="intref0325" xlink:type="simple">https://doi: 10.1038/bjc.1994.228</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib75">
                     <ce:label>[75]</ce:label>
                     <sb:reference id="sref75">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.B.</ce:given-name>
                                 <ce:surname>Rifkin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Latent transforming growth factor-β (TGF-β) binding proteins: orchestrators of TGF-β availability</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>280</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7409</sb:first-page>
                              <sb:last-page>7412</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1074/jbc.R400029200" id="intref0330" xlink:type="simple">https://doi: 10.1074/jbc.R400029200</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib76">
                     <ce:label>[76]</ce:label>
                     <sb:reference id="sref76">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Massagué</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of TGF-β signaling from cell membrane to the nucleus</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>113</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>685</sb:first-page>
                              <sb:last-page>700</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/S0092-8674(03)00432-X" id="intref0335" xlink:type="simple">https://doi.org/10.1016/S0092-8674(03)00432-X</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib77">
                     <ce:label>[77]</ce:label>
                     <sb:reference id="sref77">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pickup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Novitskiy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Moses</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The roles of TGFβ in the tumour microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>788</sb:first-page>
                              <sb:last-page>799</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1038/nrc3603" id="intref0340" xlink:type="simple">https://doi.org/10.1038/nrc3603</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib78">
                     <ce:label>[78]</ce:label>
                     <sb:reference id="sref78">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ohnuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Tosato</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Notch and TGFβ: functional partners facilitating tumor progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>OncoImmunology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>e29029</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.4161/onci.29029" id="intref0345" xlink:type="simple">https://doi.org/10.4161/onci.29029</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib79">
                     <ce:label>[79]</ce:label>
                     <sb:reference id="sref79">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Massague</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>How cells read TGF-β signals</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>169</sb:first-page>
                              <sb:last-page>178</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1038/35043051" id="intref0350" xlink:type="simple">https://doi.org/10.1038/35043051</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib80">
                     <ce:label>[80]</ce:label>
                     <sb:reference id="sref80">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Derynck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.E.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Smad-dependent and Smad-independent pathways in TGF-beta family signalling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>425</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>577</sb:first-page>
                              <sb:last-page>584</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1038/nature02006" id="intref0355" xlink:type="simple">https://doi.org/10.1038/nature02006</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib81">
                     <ce:label>[81]</ce:label>
                     <sb:reference id="sref81">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Akhurst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hata</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the TGFβ signalling pathway in disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>790</sb:first-page>
                              <sb:last-page>811</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1038/nrd3810" id="intref0360" xlink:type="simple">https://doi: 10.1038/nrd3810</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib82">
                     <ce:label>[82]</ce:label>
                     <sb:reference id="sref82">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Derynck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Akhurst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Balmain</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TGF-beta signaling in tumor suppression and cancer progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>117</sb:first-page>
                              <sb:last-page>129</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1038/ng1001-117" id="intref0365" xlink:type="simple">https://doi.org/10.1038/ng1001-117</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib83">
                     <ce:label>[83]</ce:label>
                     <sb:reference id="sref83">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Safina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Vandette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Bakin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2407</sb:first-page>
                              <sb:last-page>2422</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1038/sj.onc.1210046" id="intref0370" xlink:type="simple">https://doi.org/10.1038/sj.onc.1210046</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib84">
                     <ce:label>[84]</ce:label>
                     <sb:reference id="sref84">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Esquela-kerscher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.J.</ce:given-name>
                                 <ce:surname>Slack</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oncomirs - microRNAs with a role in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>259</sb:first-page>
                              <sb:last-page>269</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1038/nrc1840" id="intref0375" xlink:type="simple">https://doi.org/10.1038/nrc1840</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib85">
                     <ce:label>[85]</ce:label>
                     <sb:reference id="sref85">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Sartor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Mahavisno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.G.</ce:given-name>
                                 <ce:surname>Keshamouni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cavalcoli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Karnovsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kuick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.V.</ce:given-name>
                                 <ce:surname>Jagadish</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Mirel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Weymouth</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>ConceptGen: a gene set enrichment and gene set relation mapping tool</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioinformatics</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>456</sb:first-page>
                              <sb:last-page>463</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1093/bioinformatics/btp683" id="intref0380" xlink:type="simple">https://doi: 10.1093/bioinformatics/btp683</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib86">
                     <ce:label>[86]</ce:label>
                     <sb:reference id="sref86">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bueno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>de Alwis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Pitou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yingling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Glatt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.F.</ce:given-name>
                                 <ce:surname>Trocóniz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>142</sb:first-page>
                              <sb:last-page>150</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/j.ejca.2007.10.008" id="intref0385" xlink:type="simple">https://doi.org/10.1016/j.ejca.2007.10.008</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib87">
                     <ce:label>[87]</ce:label>
                     <sb:reference id="sref87">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.E.</ce:given-name>
                                 <ce:surname>Bhola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Balko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Dugger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Kuba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sánchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sanders</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Stanford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Cook</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Arteaga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>123</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1348</sb:first-page>
                              <sb:last-page>1358</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1172/JCI65416" id="intref0390" xlink:type="simple">https://doi: 10.1172/JCI65416</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib88">
                     <ce:label>[88]</ce:label>
                     <sb:reference id="sref88">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Yoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Jung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yamashita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.K.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sudo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nakae</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activin receptor-like kinase 5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EMBO Mol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1720</sb:first-page>
                              <sb:last-page>1739</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1002/emmm.201302524" id="intref0395" xlink:type="simple">https://doi: 10.1002/emmm.201302524</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib89">
                     <ce:label>[89]</ce:label>
                     <sb:reference id="sref89">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Fujiwara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nokihara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yamada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Yamamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sunami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Utsumi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Asou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ogasawara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Gueorguieva</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Chemother. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>76</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1143</sb:first-page>
                              <sb:last-page>1152</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1007/s00280-015-2895-4" id="intref0400" xlink:type="simple">https://doi: 10.1007/s00280-015-2895-4</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib90">
                     <ce:label>[90]</ce:label>
                     <sb:reference id="sref90">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rodón</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Carducci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Sepulveda-Sánchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Azaro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Calvo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Seoane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Braña</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sicart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Gueorguieva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cleverly</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Invest. N. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>357</sb:first-page>
                              <sb:last-page>370</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1007/s10637-014-0192-4" id="intref0405" xlink:type="simple">https://doi: 10.1007/s10637-014-0192-4</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib91">
                     <ce:label>[91]</ce:label>
                     <sb:reference id="sref91">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rodon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Carducci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Sepulvedasánchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Azaro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Calvo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Seoane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Braña</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sicart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Gueorguieva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Cleverly</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>553</sb:first-page>
                              <sb:last-page>560</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1158/1078-0432.CCR-14-1380" id="intref0410" xlink:type="simple">https://doi: 10.1158/1078-0432.CCR-14-1380</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib92">
                     <ce:label>[92]</ce:label>
                     <sb:reference id="sref92">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Kovacs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Maldonado</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Azaro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Fernández</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.L.</ce:given-name>
                                 <ce:surname>Romero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Sepulvedasánchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Corretti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Carducci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dolan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Gueorguieva</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cardiac safety of TGF-β receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cardiovasc. Toxicol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>309</sb:first-page>
                              <sb:last-page>323</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1007/s12012-014-9297-4" id="intref0415" xlink:type="simple">https://doi: 10.1007/s12012-014-9297-4</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib93">
                     <ce:label>[93]</ce:label>
                     <ce:other-ref id="sref93">
                        <ce:textref>D.K. Kim, Y.Y. Sheen, C. Jin, C.Y. Park, S. Domalapally, S.R. Kota, K. Maddeboina, S.V. Bala, 2-pyridyl Substituted Imidazoles as Therapeutic ALK5 And/or ALK4 Inhibitors, US8080568B1.</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib94">
                     <ce:label>[94]</ce:label>
                     <sb:reference id="sref94">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kazuhito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Kaori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yoshie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Dong-Hyun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.K.</ce:given-name>
                                 <ce:surname>Gu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Eun-Sook</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Krause</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Dong-Wook</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>140</sb:first-page>
                              <sb:last-page>148</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1111/cas.12849" id="intref0420" xlink:type="simple">https://doi: 10.1111/cas.12849</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib95">
                     <ce:label>[95]</ce:label>
                     <sb:reference id="sref95">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Connolly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Freimuth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Akhurst</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Complexities of TGF-β targeted cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Biol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>964</sb:first-page>
                              <sb:last-page>978</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.7150/ijbs.4564" id="intref0425" xlink:type="simple">https://doi: 10.7150/ijbs.4564</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib96">
                     <ce:label>[96]</ce:label>
                     <sb:reference id="sref96">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Takeuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Abe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hiasa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Oda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Amou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kido</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Harada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Tanaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Miki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nakamura</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TGF-β inhibition restores terminal osteoblast differentiation to suppress myeloma growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PloS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>e9870</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1371/journal.pone.0009870" id="intref0430" xlink:type="simple">https://doi: 10.1371/journal.pone.0009870</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib97">
                     <ce:label>[97]</ce:label>
                     <sb:reference id="sref97">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.N.</ce:given-name>
                                 <ce:surname>Min</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Son</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Nam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Sheen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>351</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>72</sb:first-page>
                              <sb:last-page>80</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1016/j.canlet.2014.05.006" id="intref0435" xlink:type="simple">https://doi: 10.1016/j.canlet.2014.05.006</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib98">
                     <ce:label>[98]</ce:label>
                     <sb:reference id="sref98">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Mohammad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Javelaud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Fournier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Niewolna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Mckenna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.H.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Duong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.K.</ce:given-name>
                                 <ce:surname>Dunn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mauviel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Guise</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>71</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>175</sb:first-page>
                              <sb:last-page>184</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1158/0008-5472.CAN-10-2651" id="intref0440" xlink:type="simple">https://doi: 10.1158/0008-5472.CAN-10-2651</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib99">
                     <ce:label>[99]</ce:label>
                     <sb:reference id="sref99">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Weinmann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cancer immunotherapy: selected targets and small-molecule modulators</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>450</sb:first-page>
                              <sb:last-page>466</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1002/cmdc.201500566" id="intref0445" xlink:type="simple">https://doi: 10.1002/cmdc.201500566</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib100">
                     <ce:label>[100]</ce:label>
                     <sb:reference id="sref100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Anderton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Mellor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sadler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pass</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Powell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Steele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Heier</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Induction of heart valve lesions by small-molecule ALK5 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Toxicol. For. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>39</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>916</sb:first-page>
                              <sb:last-page>924</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1177/0192623311416259" id="intref0450" xlink:type="simple">https://doi: 10.1177/0192623311416259</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib101">
                     <ce:label>[101]</ce:label>
                     <sb:reference id="sref101">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Amaravadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.B.</ce:given-name>
                                 <ce:surname>Thompson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The survival kinases Akt and Pim as potential pharmacological targets</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>115</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2618</sb:first-page>
                              <sb:last-page>2624</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1172/JCI26273" id="intref0455" xlink:type="simple">https://doi.org/10.1172/JCI26273</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib102">
                     <ce:label>[102]</ce:label>
                     <sb:reference id="sref102">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Losman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.P.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.Y.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kashiwada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Giallourakis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Cowan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Foltenyi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rothman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IL-4 signaling is regulated through the recruitment of phosphatases, kinases, and SOCS proteins to the receptor complex</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cold Spring Harb. Symp. Quant. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>64</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>405</sb:first-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:10.1101/sqb.1999.64.405" id="intref0460" xlink:type="simple">https://doi:10.1101/sqb.1999.64.405</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib103">
                     <ce:label>[103]</ce:label>
                     <sb:reference id="sref103">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Swords</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kelly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Carew</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nawrocki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mahalingam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sarantopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bearss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Giles</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Pim kinases: new targets for drug development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Drug Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2059</sb:first-page>
                              <sb:last-page>2066</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:10.2174/138945011798829447" id="intref0465" xlink:type="simple">https://doi:10.2174/138945011798829447</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib104">
                     <ce:label>[104]</ce:label>
                     <sb:reference id="sref104">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Akasaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Akasaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kurata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ueda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Shimizu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Uchiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ohno</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2335</sb:first-page>
                              <sb:last-page>2341</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib105">
                     <ce:label>[105]</ce:label>
                     <sb:reference id="sref105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Amson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Sigaux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Przedborski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Flandrin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Givol</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Telerman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>86</sb:volume-nr>
                              </sb:series>
                              <sb:date>1989</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8857</sb:first-page>
                              <sb:last-page>8861</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1073/pnas.86.22.8857" id="intref0470" xlink:type="simple">https://doi.org/10.1073/pnas.86.22.8857</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib106">
                     <ce:label>[106]</ce:label>
                     <sb:reference id="sref106">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.N.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Burcu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Baer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PKC412 directly inhibits the serine/threonine protein kinase Pim-1 in cell lines and acute myeloid leukemia cells as a novel mechanism of inhibition of multidrug resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:book-series>
                                 <sb:series>
                                    <sb:title>
                                       <sb:maintitle>ASH Annual Meeting Abstracts</sb:maintitle>
                                    </sb:title>
                                    <sb:volume-nr>112</sb:volume-nr>
                                 </sb:series>
                              </sb:book-series>
                              <sb:date>2008</sb:date>
                           </sb:edited-book>
                           <sb:pages>
                              <sb:first-page>2655</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib107">
                     <ce:label>[107]</ce:label>
                     <sb:reference id="sref107">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.G.</ce:given-name>
                                 <ce:surname>Jinesh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mokkapati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.E.</ce:given-name>
                                 <ce:surname>Morales</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Apoptosis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1203</sb:first-page>
                              <sb:last-page>1213</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1007/s10495-016-1289-3" id="intref0475" xlink:type="simple">https://doi.org/10.1007/s10495-016-1289-3</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib108">
                     <ce:label>[108]</ce:label>
                     <sb:reference id="sref108">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nagai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ohtani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Banham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Hancock</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pim-2 kinase influences regulatory T cell function and stability by mediating Foxp3 protein N-terminal phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>290</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>20211</sb:first-page>
                              <sb:last-page>20220</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1074/jbc.M115.638221" id="intref0480" xlink:type="simple">https://doi: 10.1074/jbc.M115.638221</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib109">
                     <ce:label>[109]</ce:label>
                     <sb:reference id="sref109">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Daenthanasanmak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Iamsawat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.D.</ce:given-name>
                                 <ce:surname>Nguyen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mehrotra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kraft</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Z.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Enhance T cell immunotherapy by targeting PIM-2 kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>128</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>815</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib110">
                     <ce:label>[110]</ce:label>
                     <sb:reference id="sref110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.L.</ce:given-name>
                                 <ce:surname>Plym</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.T.Z.</ce:given-name>
                                 <ce:surname>Plym</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Martina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Lisa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ulrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Jonas</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>448</sb:first-page>
                              <sb:last-page>460</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.18632/oncotarget.283" id="intref0485" xlink:type="simple">https://doi: 10.18632/oncotarget.283</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib111">
                     <ce:label>[111]</ce:label>
                     <sb:reference id="sref111">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Jackson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Pheneger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Pheneger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Davis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Allen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Munson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of PIM kinases in human and mouse CD4<ce:sup loc="post">+</ce:sup> T cell activation and inflammatory bowel disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>272</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>200</sb:first-page>
                              <sb:last-page>213</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1016/j.cellimm.2011.10.011" id="intref0490" xlink:type="simple">https://doi: 10.1016/j.cellimm.2011.10.011</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib112">
                     <ce:label>[112]</ce:label>
                     <sb:reference id="sref112">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Bialopiotrowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gorniak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Pula</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Noyszewska-Kania</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Makuch-Lasica</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Nowak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Szydlowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Jablonska</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Microenvironment-Induced expression of PIM kinases supports chronic lymphocytic leukemia cells survival and promotes CXCR4-mTOR pathway dependent ,igration</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>128</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e3239</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib113">
                     <ce:label>[113]</ce:label>
                     <sb:reference id="sref113">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Blanco-Aparicio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Carnero</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pim kinases in cancer: diagnostic, prognostic and treatment opportunities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>85</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>629</sb:first-page>
                              <sb:last-page>643</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/j.bcp.2012.09.018" id="intref0495" xlink:type="simple">https://doi.org/10.1016/j.bcp.2012.09.018</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib114">
                     <ce:label>[114]</ce:label>
                     <sb:reference id="sref114">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Neelapu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.N.</ce:given-name>
                                 <ce:surname>Miranda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Medeiros</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gandhi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3491</sb:first-page>
                              <sb:last-page>3500</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1182/blood-2012-02-412643" id="intref0500" xlink:type="simple">https://doi.org/10.1182/blood-2012-02-412643</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib115">
                     <ce:label>[115]</ce:label>
                     <sb:reference id="sref115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Paíno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>García-Gómez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>González-Méndez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>San</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hernández-García</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>López-Iglesias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Algarín</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Martín-Sánchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Corbacho-González</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ortiz-De-Solórzano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The novel pan-PIM kinase inhibitor, PIM447, displays dual anti-myeloma and bone protective effects, and potently synergizes with current standards of care</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clinical Cancer Research An Official Journal of the American Association for Cancer Research</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>225</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib116">
                     <ce:label>[116]</ce:label>
                     <sb:reference id="sref116">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Raab</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Ocio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Günther</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.T.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lebovic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jakubowiak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Xiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase 1 study update of the novel pan-pim kinase inhibitor LGH447 in patients with relapsed/refractory multiple myeloma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>122</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3186</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib117">
                     <ce:label>[117]</ce:label>
                     <sb:reference id="sref117">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Keane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Reidy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Natoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Raab</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>O'Dwyer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the Pim kinases in multiple myeloma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood Canc. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e325</sb:first-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1038/bcj.2015.46" id="intref0505" xlink:type="simple">https://doi: 10.1038/bcj.2015.46</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib118">
                     <ce:label>[118]</ce:label>
                     <sb:reference id="sref118">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Ambler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Anderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.P.</ce:given-name>
                                 <ce:surname>Boscoe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Bree</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Brodfuehrer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Curran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Day</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Dehnhardt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Dower</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Drozda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.K.</ce:given-name>
                                 <ce:surname>Frisbie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.K.</ce:given-name>
                                 <ce:surname>Gavrin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Goldberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hegen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hepworth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Hope</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kamtekar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.C.</ce:given-name>
                                 <ce:surname>Kilty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.E.</ce:given-name>
                                 <ce:surname>Lovering</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Lowe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Mathias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Morgan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Murphy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Papaioannou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Patny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Pierce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.R.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Saiah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.J.</ce:given-name>
                                 <ce:surname>Samardjiev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Samas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.H.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.H.</ce:given-name>
                                 <ce:surname>Soutter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Strohbach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Symanowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Thomason</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Trzupek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Vargas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vincent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Zapf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of clinical candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by fragment-based drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5521</sb:first-page>
                              <sb:last-page>5542</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1021/acs.jmedchem.7b00231" id="intref0510" xlink:type="simple">https://doi: 10.1021/acs.jmedchem.7b00231</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib119">
                     <ce:label>[119]</ce:label>
                     <sb:reference id="sref119">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Suzuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Suzuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Yeh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IRAK-4 as the central TIR signaling mediator in innate immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>503</sb:first-page>
                              <sb:last-page>506</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/S1471-4906(02)02298-6" id="intref0515" xlink:type="simple">https://doi.org/10.1016/S1471-4906(02)02298-6</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib120">
                     <ce:label>[120]</ce:label>
                     <sb:reference id="sref120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IRAK4 in TLR/IL-1R signaling: possible clinical applications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>614</sb:first-page>
                              <sb:last-page>618</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1002/eji.200838161" id="intref0520" xlink:type="simple">https://doi.org/10.1002/eji.200838161</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib121">
                     <ce:label>[121]</ce:label>
                     <sb:reference id="sref121">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Koziczak-Holbro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Littlewood-Evans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Pöllinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kovarik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Dawson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zenke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Burkhart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Müller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Gram</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arthritis Rheum.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1661</sb:first-page>
                              <sb:last-page>1671</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1002/art.24552" id="intref0525" xlink:type="simple">https://doi.org/10.1002/art.24552</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib122">
                     <ce:label>[122]</ce:label>
                     <sb:reference id="sref122">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Strelow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Fontana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wesche</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>99</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5567</sb:first-page>
                              <sb:last-page>5572</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1073/pnas.082100399" id="intref0530" xlink:type="simple">https://doi.org/10.1073/pnas.082100399</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib123">
                     <ce:label>[123]</ce:label>
                     <sb:reference id="sref123">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Suzuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Saito</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IRAK-4 – a shared NF-κB activator in innate and acquired immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>566</sb:first-page>
                              <sb:last-page>572</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1016/j.it.2006.10.003" id="intref0535" xlink:type="simple">https://doi.org/10.1016/j.it.2006.10.003</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib124">
                     <ce:label>[124]</ce:label>
                     <sb:reference id="sref124">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kawagoe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yamamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Matsui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Uematsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Takeuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Akira</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>204</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1013</sb:first-page>
                              <sb:last-page>1024</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1084/jem.20061523" id="intref0540" xlink:type="simple">https://doi: 10.1084/jem.20061523</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib125">
                     <ce:label>[125]</ce:label>
                     <sb:reference id="sref125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.H.</ce:given-name>
                                 <ce:surname>Von</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Picard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pankla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Ku</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Chrabieh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.B.</ce:given-name>
                                 <ce:surname>Mustapha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ghandil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Camcioglu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pyogenic bacterial infections in humans with MyD88 deficiency</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>321</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>691</sb:first-page>
                              <sb:last-page>696</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1126/science.1158298" id="intref0545" xlink:type="simple">https://doi: 10.1126/science.1158298</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib126">
                     <ce:label>[126]</ce:label>
                     <sb:reference id="sref126">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Puel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Eidenschenk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Ku</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Casrouge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Picard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.V.</ce:given-name>
                                 <ce:surname>Bernuth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Senechal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Plancoulaine</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Human TLR-7-, -8-, and -9-mediated induction of IFN-α/β and -λ is IRAK-4 dependent and redundant for protective immunity to viruses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunity</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>465</sb:first-page>
                              <sb:last-page>478</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://https://doi.org/10.1016/j.immuni.2005.09.016" id="intref0550" xlink:type="simple">https://https://doi.org/10.1016/j.immuni.2005.09.016</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib127">
                     <ce:label>[127]</ce:label>
                     <sb:reference id="sref127">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Ku</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.B.</ce:given-name>
                                 <ce:surname>Von</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Picard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.H.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Chrabieh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Issekutz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.K.</ce:given-name>
                                 <ce:surname>Cunningham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gallin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>204</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2407</sb:first-page>
                              <sb:last-page>2422</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1084/jem.20070628" id="intref0555" xlink:type="simple">https://doi: 10.1084/jem.20070628</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib128">
                     <ce:label>[128]</ce:label>
                     <sb:reference id="sref128">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Koziczak-Holbro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Joyce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Glück</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kinzel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Müller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Gram</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Solving the IRAK-4 enigma: application of kinase-dead knock-in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:title>
                                 <sb:maintitle>Ernst Schering Found. Symp. Proc. 2007</sb:maintitle>
                              </sb:title>
                              <sb:date>2007</sb:date>
                           </sb:edited-book>
                           <sb:pages>
                              <sb:first-page>63</sb:first-page>
                              <sb:last-page>82</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1007/2789_2007_071" id="intref0560" xlink:type="simple">https://doi.org/10.1007/2789_2007_071</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib129">
                     <ce:label>[129]</ce:label>
                     <sb:reference id="sref129">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Suzuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Suzuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Duncan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Millar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Mirtsos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Takada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wakeham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Itie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>416</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>750</sb:first-page>
                              <sb:last-page>756</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1038/nature736" id="intref0565" xlink:type="simple">https://doi.org/10.1038/nature736</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib130">
                     <ce:label>[130]</ce:label>
                     <sb:reference id="sref130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Srivastava</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Geng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Joseph</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Mckenna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bansal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ochoa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Davila</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>72</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6209</sb:first-page>
                              <sb:last-page>6216</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1158/0008-5472.CAN-12-0337" id="intref0570" xlink:type="simple">https://doi: 10.1158/0008-5472.CAN-12-0337</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib131">
                     <ce:label>[131]</ce:label>
                     <sb:reference id="sref131">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Younger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Gartenhaus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Joseph</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Baer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Davila</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>125</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1081</sb:first-page>
                              <sb:last-page>1097</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1172/JCI75821" id="intref0575" xlink:type="simple">https://doi: 10.1172/JCI75821</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib132">
                     <ce:label>[132]</ce:label>
                     <sb:reference id="sref132">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.N.</ce:given-name>
                                 <ce:surname>Kelly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Romero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chaudhary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Miao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Rui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.F.</ce:given-name>
                                 <ce:surname>Westlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kapeller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>212</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2189</sb:first-page>
                              <sb:last-page>2201</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1084/jem.20151074" id="intref0580" xlink:type="simple">https://doi: 10.1084/jem.20151074</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib133">
                     <ce:label>[133]</ce:label>
                     <sb:reference id="sref133">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Romero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Greenwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Shelley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Morin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kapeller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.F.</ce:given-name>
                                 <ce:surname>Westlin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synergistic blockade of activated B cell-like DLBCL proliferation with a selective inhibitor of IRAK4 in combination with inhibition of the B-cell receptor signaling network</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>122</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3833</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib134">
                     <ce:label>[134]</ce:label>
                     <sb:reference id="sref134">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Scott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Degorce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Anjum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Culshaw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.L.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Dillman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Dowling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Drew</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Ferguson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and optimisation of pyrrolopyrimidine inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the treatment of mutant MYD88<ce:sup loc="post">L265P</ce:sup> diffuse large B-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10071</sb:first-page>
                              <sb:last-page>10091</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1021/acs.jmedchem.7b01290" id="intref0585" xlink:type="simple">https://doi: 10.1021/acs.jmedchem.7b01290</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib135">
                     <ce:label>[135]</ce:label>
                     <sb:reference id="sref135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Kretschmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Eyob</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Buys</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Welm</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Drug Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1157</sb:first-page>
                              <sb:last-page>1168</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.2174/138945010792006825" id="intref0590" xlink:type="simple">https://doi: 10.2174/138945010792006825</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib136">
                     <ce:label>[136]</ce:label>
                     <sb:reference id="sref136">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Waltz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Eaton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Toneyearley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Hess</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Peace</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Ihlendorf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Kaestner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Degen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>108</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>567</sb:first-page>
                              <sb:last-page>576</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1172/JCI11881" id="intref0595" xlink:type="simple">https://doi.org/10.1172/JCI11881</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib137">
                     <ce:label>[137]</ce:label>
                     <sb:reference id="sref137">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Morrison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.B.</ce:given-name>
                                 <ce:surname>Wilson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Correll</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>172</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1825</sb:first-page>
                              <sb:last-page>1832</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.4049/jimmunol.172.3.1825" id="intref0600" xlink:type="simple">https://doi.org/10.4049/jimmunol.172.3.1825</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib138">
                     <ce:label>[138]</ce:label>
                     <sb:reference id="sref138">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Welm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Sneddon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Taylor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.A.</ce:given-name>
                                 <ce:surname>Nuyten</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.V.D.</ce:given-name>
                                 <ce:surname>Vijver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.H.</ce:given-name>
                                 <ce:surname>Hasegawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Bishop</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7570</sb:first-page>
                              <sb:last-page>7575</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.1073/pnas.0702095104" id="intref0605" xlink:type="simple">https://doi.org/10.1073/pnas.0702095104</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib139">
                     <ce:label>[139]</ce:label>
                     <sb:reference id="sref139">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Eyob</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Ekiz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Welm</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>OncoImmunology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>e25670</sb:comment>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.4161/onci.25670" id="intref0610" xlink:type="simple">https://doi.org/10.4161/onci.25670</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib140">
                     <ce:label>[140]</ce:label>
                     <sb:reference id="sref140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Sharda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Squadrito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>De</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Wynn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Jr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Hankey</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>187</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2181</sb:first-page>
                              <sb:last-page>2192</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi.org/10.4049/jimmunol.1003460" id="intref0615" xlink:type="simple">https://doi.org/10.4049/jimmunol.1003460</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib141">
                     <ce:label>[141]</ce:label>
                     <sb:reference id="sref141">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Eyob</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Ekiz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Derose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Waltz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Welm</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>751</sb:first-page>
                              <sb:last-page>760</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref xlink:href="https://doi:%2010.1158/2159-8290.CD-12-0480" id="intref0620" xlink:type="simple">https://doi: 10.1158/2159-8290.CD-12-0480</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>